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(29%) tumors responding to TMZ, compared with 100%, 94%, and 90%
response rates for paclitaxel, cis-platinum and vincristine, respectively.
Length of survival in TMZ-treated patients who screened positive for a
TMZ response averaged 301 days, compared with just 98 days in their
TMZ-negative counterparts. CONCLUSIONS: In this study, we report a
novel assay system that generates individual patient drug profiles and is
able to predict patient survival in TMZ-treated patients. Further research,
including a formal prospective clinical trial, may be warranted.
AI-28. ISOCITRATE DEHYDROGENASE-1 (IDH-1) EXPRESSION
DOES NOT CO-LOCALIZE WITH HYPOXIA INDUCIBLE
FACTOR-1ALPHA (HIF-1ALPHA) EXPRESSION IN GLIOMAS
Susan C. Williams 1, Matthias A. Karajannis 1, LuisChiriboga 1, Andreasvon
Deimling 2, and David Zagzag 1; 1New York University Langone Medical
Center; 2Ruprecht-Karls-Universitat Heidelberg
INTRODUCTION: Prior studies have demonstrated that mutations in the
enzyme cytosolic isocitrate dehydrogenase-1 (IDH-1) occur more commonly
in certain types of brain tumors, with the majority of secondary glioblasto-
mas having progressed from lower grade lesions with an IDH-1 mutation.
The role of IDH-1 in this progression is unclear but has been proposed to
be linked to hypoxia inducible factor-1alpha (HIF-1alpha). Using immuno-
histochemistry, we analyzed glioma samples that were positive for the
R132H IDH-1 mutation for HIF-1alpha expression to determine whether
tumors harboring this IDH-1 mutation had increased HIF-1alpha expression
and co-localization. METHODS: The New York University Langone
Medical Center Pathology database was queried for all archival surgical
specimens of glial neoplasms. Using immunohistochemistry on formalin-
fixed paraffin-embedded sections, 155 glial neoplasms were analyzed for
the R132H IDH-1 mutation. The tumors that were positive for this IDH-1
mutation were then analyzed for HIF-1alpha expression by immunohisto-
chemistry. RESULTS: Evidence of IDH-1 R132H mutated tumor cells was
present in 19 of 155 patients. Some of the tumors expressing this IDH-1
mutation also exhibited increased HIF-1alpha expression. However, we
did not observe IDH-1 and HIF-1alpha co-localization in these tumors.
CONCLUSIONS: Activation of HIF-1alpha has been implicated as a mech-
anism for tumor progression in gliomas harboring the IDH-1 mutation. Our
results do not support an in situ link between HIF-1alpha expression and the
R132H IDH-1 mutation.
AI-29. FOCAL ADHESIONS DYNAMICS IN MALIGNANT GLIAL
CELLS WITH VARIABLE DRR EXPRESSION
Abdulrazzag Ajlan , S Husaine , and K. Petrecca ; Montreal Neurological
Institute
Gliomas are the most common primary brain tumors. Regardless of the
tumor grade, except for grade 1, tumor invasion of surrounding brain
tissue is a common finding. The invasive behavior of these tumors is a
major challenge for reaching a cure from these neoplasms and a major
cause of treatment failure. DRR, a protein expressed in glioma cells, has
been shown to promote invasiveness in these tumors. It has been suggested
that DRR has a role in the cytoskeleton-focal adhesion dynamics. Focal
adhesion is not well studied in human gliomas, and the focal adhesion-
cytoskeleton interaction is less examined in gliomas than in other cell
types. We will present data of focal adhesion dynamics with variable DRR
expression in a human glioma cell line. Our work includes quantification
of focal adhesions in glioma cell lines with different DRR expression and
evaluation of the change in dynamics of focal adhesions using live-tissue
imaging obtained from the same cell lines. Our work adds to the current
knowledge of focal adhesion in gliomas. Understanding how focal adhesion
dynamics change in relation to DRR expression will improve the overall
understanding of the mechanisms involved in glioma migration.
AI-30. ONCOGENIC EGFRvIII SENSITIZES GBM CELLS TO
PROANGIOGENIC EFFECTS OF THE COAGULATION SYSTEM
NathalieMagnus , DelphineGarnier , BrianMeehan , and JanuszRak ; McGill
University Montreal Children’s Hospital Research Institute
INTRODUCTION: Tissue factor (TF) is a procoagulant receptor fre-
quently overexpressed in human glioblastoma multiforme (GBM), in
which thrombotic events are particularly frequent. Analysis of GBM cell
lines suggests that TF is a regulatory target of several major genetic altera-
tions associated with this disease, including activation of the epidermal
growth factor receptor (EGFR) and expression of its mutant (EGFRvIII)
(Milsom et al., 2008). Upon binding the coagulation factor VIIa, TF drives
extracellular (procoagulant) and intracellular (signaling) events. The latter
are mediated by protease activated receptors 1 and 2 (PAR-1/2) and are
implicated in cancer progression and angiogenesis. This raises the question
whether and how TF signals intersect with oncogenic effects of EGFRvIII.
METHODS: U373 and U87 glioma cells lines and their EGFRvIII expressing
or TF transfected counterparts were compared for growth in vivo and
FVIIa-dependent procoagulant activities (Xa generation assay), expression
of TF and PAR1/2 (RT-PCR, ELISA), and production of angiogenic
factors (VEGF and IL-8). RESULTS: We found that EGFRvIII upregulates
TF, PAR-1, PAR-2, and FVII in GBM cell lines, which also become highly
procoagulant and hypersensitive to stimulation with FVIIa, PAR-1, and
PAR-2 activating peptides. This stimulation evokes production of VEGF
and IL-8 in EGFR/EGFRvIII-expressing GBM cells, but not in their indolent
counterparts transfected with TF alone (TF-U373). However, TF transfec-
tion renders indolent GBM cells capable of forming tumors, but only after
a long latency. CONCLUSIONS: TF signaling intersects with and amplifies
the proangiogenic effects of EGFRvIII-driven oncogenic pathways, and TF
also may have an independent but modest role in GBM progression.
CELL BIOLOGY AND SIGNALING
CB-01. REGULATION OF AMINOACYLASE EXPRESSION IN
NEUROBLASTOMA
Patrick M. Long 1, Umadevi V. Wesley 2, and Diane M. Jaworski 3;
1Department of Anatomy and Neurobiology, University of Vermont College
of Medicine; 2Department of Microbiology and Molecular Genetics,
University of Vermont; 3Department of Anatomy and Neurobiology,
University of Vermont College of Medicine, Burlington
Neuroblastoma, a cancer of the sympathetic nervous system, is the most
common extracranial solid tumor in children. MYCN amplification and
increased BDNF/TrkB signaling are features of high-grade tumors, yet only
25% of malignant tumors display those features. Thus, the identification
of additional biomarkers and therapeutic targets is essential. Since aminoacy-
lase 1 (ACY1), an amino acid deacetylase, is a putative tumor suppressor in
small cell lung and renal cell carcinomas, we investigated whether ACY1 or
family members aspartoacylase (ASPA, aminoacylase 2) or aminoacylase 3
(ACY3) could serve a similar function in neuroblastoma. Aminoacylase
expression was examined in TrkB-positive, MYCN-amplified SMS-KCNR
and TrkB-negative, non-MYCN amplified SK-N-AS and SK-N-SH neuroblas-
toma cell lines. ACY1 and ASPA exhibited distinct spatial localization in
SMS-KCNR and SK-N-SH cells, while ACY3 displayed nuclear expression
in all three lines examined. ACY1 was the only aminoacylase whose
expression was up-regulated upon neuronal differentiation of SK-N-SH
cells in media containing 10% serum. ASPA expression was greater in the
least aggressive SK-N-SH line and significantly reduced in the most aggressive
SMS-KCNR line. Conversely, ACY3 expression was highly expressed in the
most aggressive SMS-KCNR cells. In vivo, aminoacylases are expressed in
common sites of neuroblastoma origin. Bioinformatics data mining of
Kaplan-Meier survival data revealed that high ACY3 expression is correlated
with poor prognosis and that low expression of ACY1 or ASPA is also corre-
lated with poor prognosis, suggesting that the loss of these aminoacylases may
contribute to neuroblastoma tumorigenesis.
CB-02. NPAS3 IS A LATE-STAGE-ACTING PROGRESSION
FACTOR IN GLIOMAS WITH TUMOR SUPPRESSIVE
FUNCTIONS
Manjit Rana 1, Tim-Rasmus Kiehl 2, Kelvin So 2, Peter Gould 3,
Norbert Ajewung 4, and Deepak Kamnasaran 4; 1Centre de recherche du
CHUL; 2University Health Network; 3CHAUQ Hôpital de l’Enfant-Jésus;
4Laval University
BACKGROUND: Malignant astrocytomas, the most common primary
brain tumors, are predominantly fatal with current therapies. In our effort
to better understand the biology of astrocytomas, we explored new thera-
peutic targets. We previously cloned NPAS3, a transcription factor that
maps to human chromosome 14. Our principal aim is to comprehend the
disease associations of NPAS3, since we recently identified its expression
in human astrocytes. We initially identified NPAS3 as an astrocytoma candi-
date based on the Cancer Genome Project reporting chromosome 14 del-
etions (with NPAS3) among 20%-80% of astrocytomas and with
.70% of our human astrocytoma panel (n ¼ 433) having aberrant NPAS3
protein expression. Based on the findings from our precursory screen, we
next undertook functional analyses of NPAS3 in human astrocytomas.
METHODS-RESULTS: After undertaking extensive functional analyses,
we now have evidence supporting NPAS3 as an astrocytoma tumor
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suppressor involved in late-stage tumor progression, based on: 1) Aberrant
NPAS3 expression is predominant in surgically resected high-grade astrocy-
tomas compared with low-grade astrocytomas; 2) loss-of-function mutations
in NPAS3, which are associated with loss of heterozygosity of the NPAS3
locus, are identified in surgically resected human glioblastomas; 3) absent
NPAS3 expression is predominant in malignant human glioma cell lines;
4) over-expressed NPAS3 in malignant glioma cell lines suppresses trans-
formation potential, while converse reduced expression promotes an increase
in transformation potential; and 5) a reduced NPAS3 expression (efficiency
.90%) in concert with other gliomagenesis genes can transform a well-
characterized TERT immortalized human astrocyte cell line and promote
the growth of malignant astrocytomas. CONCLUSIONS: Our data
provide compelling evidence that the NPAS3 gene is involved in the cause
of astrocytomas, with tumor suppressive and late-stage acting progression
factor roles. Current research is focused on better understanding NPAS3 in
gliomas using other pre-clinical models.
CB-03. 2-DEOXY-D-GLUCOSE INHIBITS N-GLYCOSYLATION
IN GLIOBLASTOMA-DERIVED CANCER STEM CELLS
Mark R.Emmett 1, XuWang 1, Alan G.Marshall 1, YongjieJi 2, IzabelaFokt 2,
Stanislaw Skora 2, Charles A. Conrad 2, and Waldemar Priebe 2; 1National
High Magnetic Field Lab; 2The University of Texas MD Anderson Cancer
Center
Cancer stem cells (CSCs) are capable of unlimited self-renewal and multi-
lineage differentiation. We have shown that 2-deoxy-D-glucose (2-DG), a
known inhibitor of glycolysis, can inhibit the growth of glioma-derived stem
cells (GSC11) under normoxic conditions, and we hypothesize that 2-DG
affects the formation of N-glycans by replacing D-mannose in glycosylation
processes. We have synthesized 2-DG, D-glucose, and D-mannose labeled
with deuterium at C-2 and treated GSC11 cells with these monosaccharides
to measure their effects on global N-glycan formation. N-glycans were
released with PNGase F and purified over a graphitized carbon cartridge
SPE. Oligosaccharides were separated with a TSK-Gel Amide80 column
under hydrophilic interaction chromatography conditions and analyzed by
positive ion-microelectrospray with an LTQ 14.5 T FT-ICR mass spec-
trometer [1]. Data showed that deuterium-labeled 2-DG was incorporated
into the N-glycans, leading to the termination of the extension of the oligosac-
charide chain. Comparative glycomic analysis of control, 2-DG-treated, and
D-mannose-rescued GSC11 cells revealed a distinct modulation of the
N-glycan profile. The levels of all types of N-glycans were decreased (by
4-fold) in 2-DG-treated GSC11 cells compared with control cells. In con-
trast, N-glycan synthesis in GSC11 cells could be rescued to almost “normal
control” levels by adding exogenous D-mannose. D-mannose rescue of
2-DG-treated GSC11 cells drastically reduced the incorporation of 2-DG
into the N-glycans. These results indicate that 2-DG can interfere with
biochemical transformations of D-mannose and that such interference might
contribute to the overall antitumor effects of 2-DG. ([1] Schaub T M,
Hendrickson C L, Horning S, Quinn J P, Senko M W, and Marshall A G.
High performance mass spectrometry: Fourier transform ion cyclotron
resonance at 14.5 Tesla. Anal. Chem. 2008, 80, 3985-3990.)
CB-04. UNDERSTANDING AND TARGETING
KINASE-INDEPENDENT ACTIVITY OF EGFR AND
EGFRVIII TO OVERCOME GBM DRUG RESISTANCE
HuZhu , XinyuCao , SteveKeir , FrancisAli-Osman , and Hui-WenLo ; Duke
University
Glioblastoma (GBM) is the most common and most intractable brain
malignancy in adults. Patients with GBM have a dismal prognosis, with a
median survival of 12–14 months. Epidermal growth factor receptor
(EGFR) and its constitutively activated variant EGFRvIII are linked to
GBM resistance to therapy; the mechanisms underlying this association,
however, are still unclear. Also unclear are the mechanisms underlying the
resistance of GBM to EGFR-targeted monotherapy and combination
therapy. We report here that in GBM cell lines, xenografts, and primary
specimens (N ¼ 101), EGFR and EGFRvIII paradoxically co-express with
p53-upregulated modulator of apoptosis (PUMA), a proapoptotic member
of the Bcl-2 family of proteins primarily located on the mitochondria,
unlike other BH3-only proteins. Mitochondrial PUMA is known to bind
to and antagonize antiapoptotic Bcl-2/Bcl-xL/Mcl-1 and also to associate
with and activate the apoptotic executor Bax, together leading to apoptotic
response upon appropriate stress. Our results showed that both EGFR and
EGFRvIII bind to PUMA constitutively and under apoptotic stress, sub-
sequently sequestering PUMA in the cytoplasm. EGFR siRNA-mediated
expression knockdown relocates PUMA from the cytoplasm onto the mito-
chondria. The EGFR-PUMA interaction is independent of epidermal growth
factor (EGF)-induced EGFR activation and is sustained under treatment with
an EGFR kinase inhibitor, Iressa. Although GBM cells express several proa-
poptotic members of the Bcl-2 protein family, our results indicate that
PUMA is essential for therapy-induced apoptosis and thus for drug sensi-
tivity. Importantly, we found that Bcl-2/Bcl-xL/Mcl-1 inhibitors (BH3
mimetics) that mimic PUMA’s antiapoptotic activity sensitize EGFR- and
EGFRvIII-expressing GBM cells to Iressa. Collectively, we uncovered a
novel kinase-independent function of EGFR and EGFRvIII that contributes
to GBM resistance to EGFR kinase inhibition and apoptosis-inducing
agents and also provides a rationale for targeting kinase-dependent and
-independent activities of EGFR as a novel combination therapy for GBM.
CB-05. NEW THERAPEUTIC APPROACH FOR BRAIN TUMORS:
INTRANASAL ADMINISTRATION OF RAS INHIBITOR
PERILLYL ALCOHOL
Clovis O. Da Fonseca ; Fluminense Federal University
PURPOSE: The monoterpene perillyl alcohol (POH), a Ras inhibitor with
the potential capacity to arrest gliomagenesis, is being used in a phase I/II
clinical trial in adults with recurrent malignant glioma. The present study
aimed to investigate the efficacy of the intranasal administration of POH
and the survival rate in patients with recurrent glioblastoma (GBM) in com-
parison with a historical control group of GBM patients. PATIENTS AND
METHODS: The study included 89 adults with recurrent GBM who received
daily intranasal administration of 440 mg POH and 52 matched GBM
patients as the historical control group. RESULTS: The 6-month
progression-free survival (stable disease) rate was 48.3% for POH-treated
patients, with a significant (p ¼ 0.0001) survival advantage compared with
the untreated historical control group. The median survival time for patients
with secondary GBM was 11.2 months, longer (p ¼ 0.0002) than for
patients with primary GBM (5.9 months). Age-adjustment multivariate
analysis showed a significant difference (p ¼ 0.0002) in the survival rate
between primary and secondary GBM patients. Patients with tumors loca-
lized in deep regions (e.g., thalamus, basal ganglia) survived longer (p ¼
0.0083) than those with tumors in lobar regions. Radiographic improvement
and reduction of corticosteroid dosage (36%) was further associated with a
delay in progression. CONCLUSION: Intranasal administration of POH
increased the overall survival of patients with recurrent GBM compared
with historical controls, especially of patients with secondary GBM and
those with tumor localized in deep regions of the brain, without clinical evi-
dence of side effects for more than a year.
CB-06. ROLE OF A NOVEL NF1-LRPPRC INTERACTION IN RNA
GRANULE TRANSPORT
Vedant Arun 1, Joseph C. Wiley 2, Harpreet Kaur 3, and Abhijit Guha 2;
1University of Toronto; 2University of Toronto, Toronto; 3University of
Western Ontario
INTRODUCTION: Loss of function mutations and deletions in the neu-
rofibromin tumor suppressor gene underlie neurofibromatosis type 1
(NF1), which, with a birth incidence of 1 in 3000, is the most common inher-
ited tumor-predisposing syndrome in humans. While the molecular mechan-
isms that contribute to the neoplastic manifestations have been attributed to
Ras-GTPase activating protein (GAP) activity mediated through the GAP
related domain (GRD) of NF1, there is no definite consensus on the molecu-
lar etiology of the non-neoplastic phenotypes, which may be mediated by
domains outside the GRD. METHODS/RESULTS: A number of
GST-tagged NF1-domain constructs coupled with differential mass spec-
trometry (MS) analysis identified the leucine-rich pentatrico peptide repeat-
motif containing protein (LRPPRC) and dynein as previously unreported
NF1-tubulin binding domain (TBD) interacting proteins. The interaction
with LRPPRC links NF1 with Leigh’s Syndrome, the French Canadian
variant (LSFC), a neurodegenerative disorder caused by mutations in the
LRPPRC gene. Using a number of in vitro, in situ, and in silico techniques,
we identified the binding regions of the two proteins necessary and sufficient
for the interaction and determined the binding affinity to be high. Toward
elucidating the biological relevance of the interaction, we established that
the NF1-LRPPRC interaction occurs predominantly along microtubules
and complexes with motor proteins. Since LRPPRC is an RNA binding
protein and its Drosophila homologue, bicoid stability factor, stabilizes
and translocates mRNA along microtubules, we hypothesized that
NF1-LRPPRC is part of an RNA granule complex. Demonstration of
RNA binding proteins, ribosomal subunits, and RNAs complexing with
NF1-LRPPRC is highly supportive. CONCLUSIONS: NF1-LRPPRC is a
novel interaction and part of an RNA granule complex. Ongoing studies
are focused on elucidating the functional relevance of this complex, specifi-
cally in the context of neuronal maturation in Nf+/2 neurons and its role
in cognitive issues that are highly prevalent in NF1 patients.
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CB-07. KETOGENIC DIET AS AN ADJUVANT THERAPY TO
RADIATION AND THE EFFECTS ON SAPK/JNK PROTEIN
EXPRESSION
Kathryn Fenton 1, Mohammed G. Abdelwahab 1, Phillip Stafford 2, Jong
M. Rho 1, Mark C. Preul 1, and Adrienne C. Scheck 1; 1Barrow Neurological
Institute; 2Arizona State University
Glioblastoma multiforme (GBM) is an aggressive tumor. Despite surgery,
radiation, and chemotherapy, median survival is 12–18 months. More effec-
tive therapy is needed, and one promising treatment is the ketogenic diet
(KD), which has been shown to increase survival in mouse models. To
dissect KD’s mechanism of action, we did gene expression profiling on
tumor and contralateral normal brain from animals fed KD or standard
diet (SD). Mitogen-activated protein kinase (MAPK) is one pathway affected
by the diet. Within the MAPK pathway, stress-activated protein kinase/c-jun
N-terminal kinase (JNK) decreased 1.8-fold in animals fed KD. Total and
phosphorylated JNK were evaluated through Western blot (WB) analysis
and immunofluorescence. Although there was no obvious difference shown
by WB, immunofluorescence suggested an increase in total JNK in SD
versus KD. Phospho-SAPK/JNK(p-46) (phospho-JNK) was over-expressed
in tumor versus non-tumor, irrespective of diet. Additionally, immunofluor-
escence results showed that the JNK2 isoform translocated into the nucleus
in tumors in SD animals but not in KD animals. Because therapy for GBMs
typically includes radiation and/or chemotherapy, we used radiation with
and without KD. KD plus radiation extended the survival of animals com-
pared with those given either treatment alone. Expression profiling analyses
demonstrated a global effect on gene expression following radiation. We
have shown that the expression of some genes reverts closer to control
(SD) levels when animals are fed KD. Expression analysis of diet plus radi-
ation treatment indicates that some of the expression altered by radiation
is minimized by KD. Total JNK is increased in tumors in animals that
receive KD plus radiation. Phospho-JNK is increased in all groups treated
with radiation, irrespective of diet. Protein expression alterations and acti-
vation of JNK can alter growth, apoptosis, and angiogenesis. Our data
suggest a complex interaction between metabolic alterations such as those
that occur with KD and treatment response.
CB-08. DIFFERENTIAL CONTRIBUTION OF CLASSIC RAS AND
R-RAS PROTEINS TO PROLIFERATIVE AND MIGRATORY
PHENOTYPE IN MALIGNANT PERIPHERAL NERVE SHEATH
TUMORS
Nicole M. Brossier and Steven L. Carroll ; University of
Alabama-Birmingham
We hypothesized that multiple neurofibromin-regulated small G-proteins
from the classic Ras (H, N, and K-Ras) and R-Ras (R-Ras, R-Ras2, and
M-Ras) subfamilies promote the proliferation and migration of malignant
peripheral nerve sheath tumor (MPNST) cells. We found that H-Ras,
N-Ras, and R-Ras2 proteins were uniformly expressed in 8 MPNST lines;
their expression of K-Ras2b and R-Ras was variable, while M-Ras protein
was not detected in these lines. RT-PCR analyses demonstrated that the
guanine nucleotide exchange factors necessary to activate these Ras proteins
were also present. Using 3H-thymidine incorporation and Transwell
migration assays, we assessed the effects that dominant negative (DN)
H-Ras and R-Ras mutants exerted on MPNST cells. We found that DN
H-Ras and DN R-Ras both inhibited MPNST mitogenesis, while only DN
R-Ras inhibited migration. Raf-1 RBD affinity assays performed in
MPNST cells transiently transfected with Myc-tagged H-Ras, N-Ras, and
K-Ras demonstrated that all 3 classic Ras proteins were constitutively acti-
vated. However, shRNA-mediated ablation of N-Ras or K-Ras had no
effect on proliferation. We conclude that both classic Ras and R-Ras subfam-
ily members contribute to MPNST pathogenesis. Inhibition of multiple Ras
isoforms will therefore likely be required to achieve an optimal therapeutic
effect. (This work was funded by R01 CA122804 and F30 NS063626.)
CB-09. IN SITU PROXIMITY LIGATION-BASED ANALYSIS
REVEALS ABERRANT DIMERIZATION AND ACTIVATION OF
EPIDERMAL GROWTH FACTOR RECEPTORS PREVALENT IN
GLIOBLASTOMA MULTIFORME
Aaron Gajadhar and Abhijit Guha ; The Hospital For Sick Children
Aberrations in epidermal growth factor receptor (EGFR/ErbB1) signaling
are the most common oncogenic stimuli in human glioblastoma multiforme
(GBM). Interactions between mutant and wild-type ErbB family members in
GBMs are of biological and potential therapeutic importance. Recently, we
have described our work developing and optimizing a novel in situ proximity
ligation assay (PLA) for dimerization and activation analysis of EGFR
mutants prevalent in GBMs. Utilizing our novel in situ platform for EGFR
dimerization analysis, we seek to directly ascertain the dimerization capacity
and activation status among EGFR mutants and ErbB members in GBM
operative specimens and whether this feature has important prognostic or
diagnostic value in GBMs harboring them. Our initial in vitro analysis
using this platform demonstrates the aberrant homo-/hetero-dimeric proper-
ties of EGFRvIII and EGFRc958 mutants, the two most common mutants
associated with EGFR amplification in GBMs. In addition, dimer
phospho-activation status can be detected with .16-fold sensitivity and
.17-fold SNR than phospho-EGFR measurements currently undertaken
with IHC or IF. Dimer activation analysis indicates the aberrant activation
properties of mutant dimers that may be associated with oncogenic down-
stream signaling. Furthermore, we report for the first time the detection of
wild-type and EGFRvIII dimerization in GBM specimens, in keeping with
our prior cell line data. GBM tissue microarray analysis for the presence of
this mutant heterodimer has commenced for statistical examination with
patient survival. We propose the PLA analysis platform as an alternative
diagnostic modality to evaluate the expression, dimerization, and activation
of wild-type and mutant EGFRs prevalent in GBMs and whether these fea-
tures have important prognostic or diagnostic value. Moreover, since PLA
allows specimen assessment of not only expression and activation but also
dimerization, which is not evaluated by current IHC techniques, it will
likely serve as a way to evaluate promising anti-EGFR strategies directed
at preventing EGFR dimerization and activation.
CB-10. RAS REGULATED OVER-EXPRESSION OF INHIBITORS
OF APOPTOSIS PROTEIN (IAPS) IN GLIOMAGENESIS
JoydeepMukherjee 1, AmparoWolf 1, CynthiaHawkins 2, and AbhijitGuha 3;
1Arthur & Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick
Children; 2Department of Pathology, The Hospital for Sick Children;
3Department of Neurosurgery, Western Hospital and The Hospital for Sick
Children
INTRODUCTION: Transformation requires aberrant proliferation
through signaling pathways such as Ras and inhibition of apoptosis.
Toward apoptosis in glioblastoma multiforme (GBM), little is known about
the expression and function of a family of proteins known as inhibitors of
apoptosis proteins (IAPs), which include cIAP1, cIAP2, XIAP and survivin.
Human tumors with activating Ras mutations produce high amounts of survi-
vin. We hypothesize that elevated activity of Ras in GBMs, which do not
harbor primary Ras mutations, results in aberrant expression of IAPs in
GBMs and plays a role in glioma transformation. METHODS/RESULTS:
Our previously described GFAP:12V-HaRas (RasB8) mouse glioma model
was utilized, with resultant gliomas demonstrating increased expression of
XIAP and survivin. Increased XIAP and survivin was also present in estab-
lished human GBM cells, with elevated Ras activity. Knockdown of Ras
activity with the dominant-negative Ha-Ras N17 in established human
GBM cell lines significantly decreased XIAP and survivin levels. XIAP and sur-
vivin were also directly decreased by siRNA, with both strategies increasing
sensitivity to apoptosis-inducing chemotherapy. Stimulation of these lines
with TGF-a to induce Ras activation increased XIAP and survivin expression,
an effect that was reversed by MEK inhibitors. CONCLUSIONS: These in
vitro studies will be complemented by in vivo studies involving the breeding
of our RasB8 glioma model to double transgenics with GFAP-Cre regulated
decreased expression of survivinflox/flox in astrocytes, with a postulated
decrease in gliomagenic potential. The results to date and those under way
are highly suggestive of the thesis that elevated Ras activity leads to glial trans-
formation by not only mitogenic signals but also cooperative expression of
antiapoptotic proteins such as IAPs.
CB-11. MIR-21 AND MIR-128 DEREGULATION IN
GLIOBLASTOMA: EFFECT OF MIRNA MODULATION ON CELL
VIABILITY
P. Costa 1,2, A.L.C. Cardoso 1, L. Pereira de Almeida 1,3, M.C. Pedroso de
Lima 1,2, P. Canoll 4, and J. Bruce 5; 1Center for Neuroscience and Cell
Biology, University of Coimbra, 3004-517 Coimbra, Portugal; 2Department
of Life Sciences, Faculty of Science and Technology, University of Coimbra,
Apartado 3126, 3001-401 Coimbra, Portugal; 3Faculty of Pharmacy,
University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa
Comba, 3000-548 Coimbra, Portugal; 4Department of Pathology and Cell
Biology, Columbia University, New York, NY 10032, USA; 5Department of
Neurosurgery, Gabriele Bartoli Brain Tumor Research Laboratory Columbia
University, New York, NY, USA
The discovery of microRNAs (miRNAs), small non-coding RNAs that
regulate post-transcriptionally the expression of messenger RNAs, has
revealed an additional level of finetuning of the genome. miRNA alterations
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have been associated with development and progression of cancer, and
several miRNAs were found to be implicated in the modulation of glioma
oncogenesis. In this work, it is demonstrated that miR-21 and miR-128
expression is markedly altered in a retrovirally-induced murine model of
glioblastoma. Furthermore, miR-21 and miR-128 expression is shown to
be significantly altered in human glioblastoma specimens (n ¼ 22) and cell
line (U87) compared with control brain tissues. miR-21 is overexpressed in
80% of the tumor samples, with an average fold change value of 7.0,
whereas miR-128 is highly downregulated in all samples, with an average
fold change value of 15.6. Remarkably, analysis of the Cancer Genome
Atlas Research Network data on 252 human glioblastomas reveals miR-21
upregulation and miR-128 downregulation in all the cases, corroborating
our experimental data. Identifying the regulatory mechanisms of these aber-
rantly expressed miRNAs in glioblastoma may be critical to better under-
stand their role in initiation and progression of human glioblastoma, thus
helping in the development of effective RNA-based therapeutic approaches
for this disease.
CB-12. DOES THE MICRORNA CLUSTER OF 53 MIRNAS ON
CHROMOSOME 14Q32.31 PLAY A ROLE IN GLIOMAS?
IrisLavon 1, AvitalGranit 1, OfiraEinstein 2, TamirBen-Hur 2, and TaliSiegal 1;
1Gaffin Center for Neuro-Oncology, Hadassah University Medical Center;
2Neurology Department, Hadassah University Medical Center
BACKGROUND: We previously demonstrated that miRNAs from the
cluster of 53 miRNAs on chromosome 14q32.31 are down-regulated in
gliomas. Because this region is frequently either deleted or genetically
altered in several malignancies, it might be assumed to represent a large
tumor suppressor miRNA cluster. Our aim was to study the function of indi-
vidual miRNAs from this cluster in gliomas. METHODS: miRNAs from
chromosome 14q32.31 were cloned as a pri-microRNA into a lentivirus-
based vector. U87MG (human) and GL261 (mouse) glioma cell lines were
transduced with either a lentivirus-based-vector containing one of the
miRNAs mir-323-3p, mir-369-3p, mir-433 or with an empty vector.
Expression of the mature miRNAs was evaluated by real-time RT-PCR.
The effects of each miRNA on proliferation, migration, and soft agar
colony formation were determined in both cell lines in vitro. Based on the
in vitro results, the antitumorigenic potential of mir-323-3p was also evalu-
ated in vivo. RESULTS: Over-expression of mir-323-3p and mir-369-3p in
U87MG but not in GL261 demonstrated morphological changes that
resulted in sphere-like growth pattern even when cells were grown on com-
plete medium. The expression of these two miRNAs reduced the prolifer-
ation and migration rate of both glioma cell lines, while over-expression of
mir-433 did not induce any effect. None of the tested miRNAs had any
effect on colony formation on soft agar. Moreover, mir-323-3p prolonged
the life span of mice implanted with gliomas that over-express this
miRNA. CONCLUSIONS: miRNA members derived from the miRNA
cluster in chromosome 14q32.31 might play a role in gliomas. The antitu-
morigenic potential of these miRNA will be further studied in vitro and in
vivo using additional miRNAs from this cluster. Additionally, we will inves-
tigate the mechanism of action of these miRNAs by exploring and validating
their target genes. Further investigation is needed to uncover their role in
gliomagenesis.
CB-13. KIAA0495/PDAM IS FREQUENTLY DOWN-REGULATED
IN OLIGODENDROGLIAL TUMORS, AND ITS
DOWN-REGULATION BY SIRNA INDUCES CISPLATIN
RESISTANCE IN GLIOMA CELLS
Jesse C. Pang 1, Wai Sang Poon 1, Liangfu Zhou 2, and Ho-Keung Ng 1; 1The
Chinese University of Hong Kong; 2Fudan University
Co-deletion of chromosomes 1p and 19q is a common event in oligoden-
droglial tumors (OTs), suggesting the presence of OT-related genes. The aim
of this study was to identify target genes residing in the minimally deleted
regions on chromosome 1p36.31-p36.32 that might be involved in OTs. A
novel gene, KIAA0495/PDAM (for p53-dependent apoptosis modulator),
was found to be frequently deregulated, with 37 of 58 (63.8%) OTs exam-
ined showing reduced PDAM transcript by at least two-fold and 19 of
those exhibiting .10-fold reduced expression relative to the mean
expression level of eight normal brain samples. PDAM down-regulation
was associated with chromosome 1p loss status (P ¼ 0.001). Promoter
hypermethylation of PDAM was detected in 30 of 37 (81.1%) OTs with
reduced PDAM expression, and the two parameters were significantly
associated (P ¼ 0.0004). Glioma cells (A172 and TC620) treated with 5-
azacytidine exhibited significant enhancement of PDAM expression.
Notably, combined treatment with 5-azacytidine and trichostatin A
showed a synergistic effect on PDAM level. These findings suggest that
chromosome 1p loss and epigenetic modification are the major mechanisms
contributing to PDAM down-regulation. The role of PDAM in chemosensi-
tivity was also evaluated. PDAM knockdown had no effect on sensitivity to
vincristine, lomustine, temozolomide, and paclitaxel but could induce cispla-
tin resistance in glioma cells harboring wild-type p53. BCL2L1 exhibited sig-
nificant up-regulation, while BCL2 showed partial derepression in
PDAM-silenced cells after cisplatin treatment, suggesting that alteration of
antiapoptotic genes contributed in part to cisplatin resistance. Knockdown
of BCL2L1 abrogated the induced cisplatin-resistant phenotype.
Collectively, these findings suggest that PDAM deregulation may play a
role in OT development and that PDAM may possess the capacity to modu-
late apoptosis via regulation of p53-dependent antiapoptotic genes.
CB-14. THE HUMAN CYTOMEGALOVIRUS IE1 PROTEIN
CONFERS RESISTANCE TO TEMOZOLOMIDE IN THE U87MG
CELL LINE
Richard A. Rovin 1, Johnathan E. Lawrence 2, Justin J. Segula 2, and Robert
J. Winn 2; 1Upper Michigan Brain Tumor Center; 2Northern Michigan
University
INTRODUCTION: Human cytomegalovirus (HCMV) DNA and protein
are found in gliomas but not in normal brain or other primary brain tumors.
The role of HCMV infection in glioma biology is unclear. While it is unlikely
that HCMV infection causes glioma, viral proteins might impart a prolifera-
tive and antiapoptotic phenotype that confers a survival advantage. Does this
oncomodulation translate into a clinically relevant effect in glioma cells? To
answer this question, we compared the response of the U87IE1 and U87MG
malignant glioma cell lines to temozolomide. U87IE1 cells are U87MG cells
that have been genetically engineered to produce HCMV IE1 protein. (The
U87IE1 cell line is a generous gift from Charles Cobbs.) METHODS:
Approximately 5,000 U87IE1 and U87MG cells in normal culture media
were placed into wells of a 96-well plate. After 24 hours, the media was
replaced with culture media containing temozolomide in increasing concen-
tration. After 48 hours, cell viability was assessed using a luminescent assay.
A dose-response curve for each cell line was generated using statistical soft-
ware. The concentration of temozolomide resulting in 50% of cell death (the
EC50 value) for each cell line was determined. Results: The EC50 for temozo-
lomide in the U87MG cell line is 565.6 micromolar, while in the U87IE1 cell
line it is 1319 micromolar. This difference is statistically significant (p ,
0.0001) and indicates that the U87IE1 cells are more resistant to temozlo-
mide than are the U87MG cells. CONCLUSION: HCMV IE1 expression
by U87MG cells enhances their proliferation and survival. In this study,
we show that this oncomodulatory effect is clinically relevant: the U87IE1
cell line is more resistant than the U87MG cell line to temozolomide. This
finding suggests that HCMV is a viable treatment target for patients with
glioma.
CB-15. TARGETING MICRORNAS IN GLIOMA CELLS WITH
ANTINEOPLASTONS
Sonali Patil , Stanislaw R. Burzynski , Emilia Mrowczynski , and
Krzysztof Grela ; Burzynski Research Institute
MicroRNAs (miRNAs) are short, endogenous, non-protein-coding, single-
stranded sequences of RNA that have been found to play an important regu-
latory role in gene expression. The genes encoding miRNA are often located
in genomic regions associated with cancer; hence, it has been suggested that
miRNAs may be tumor suppressors or oncogenes. Recently, several miRNAs
that are deregulated in glioblastomas have been studied, and their target
genes and pathways have been identified. In this study, we report the
changes in expression of several miRNAs in U87 glioblastoma cells in
response to exposure to antineoplaston AS2-1. This study was done using
the Dharmacon miRNA profiling array (Thermo Fisher Scientific). The
miRNAs 125a-5p and 125a-3p are some of the miRNAs up-regulated in
our study; 125a-5p has recently been shown to be regulated by the epidermal
growth factor receptor and to function as a tumor suppressor in lung cancer.
It has also been shown that the over-expression of miRNA 125a or miRNA
125b caused reduced migration and invasion of SKBR3 breast cancer cells.
Using the total human microarray screen (Affymetrix) we have noted the
reduced expression of AKT2 and the enhanced expression of genes involved
in apoptosis in U87 cells exposed to antineoplaston AS2-1. Antineoplastons
will be used in phase III U.S. Food and Drug Administration-regulated clini-
cal trials this year. Once approved, these amino acid derivatives may offer
promising treatment in many types of brain tumors.
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CB-16. SHP-2/PTPN11 IS A CRITICAL MEDIATOR OF
GLIOMAGENESIS DRIVEN BY PDGFR-ALPHA AND INK4A/ARF
ABERRATIONS
Shiyuan Cheng 1, Kunwei Liu 1, Haizhong Feng 1, Robert Bacho 2,
Andrius Kazlauskas 3, Erin M. Smith 4, Karen Symes 4, and Bo Hu 1;
1University of Pittsburgh; 2University of Texas Southwestern Medical
Center; 3Schepens Eye Research Institute; 4Boston University
Glioblastoma is the most common and aggressive cancer of the central
nervous system. Recent collaborative efforts have classified glioblastomas
into four clinically relevant subtypes based on signature genetic lesions in
the tumor specimens. In a large number of proneural glioblastomas,
PDGFR-alpha over-expression is concomitant with a loss of CDKN2A
locus (encoding p16INK4a and p14ARF). In this study, we demonstrate
that activation of PDGFR-alpha and/or PDGF-A confers tumorigenicity to
Ink4a/Arf-deficient mouse astrocytes or human glioma cells in the brain.
Restoration of p16INK4a but not p19ARF suppresses PDGFR-alpha-
promoted glioma formation. Conversely, cellular depletion of endogenous
p16/INK4a by short hairpin RNA (shRNA) in glioma cells with wild-type
INK4a/ARF markedly enhanced PDGFR-alpha-induced transformation.
Mechanistically, the abrogation of intrinsic tyrosine kinase activity of
PDGFR-alpha or the inhibition of signaling modules in PDGFR-alpha that
lost the capacity to bind to PI3K or SHP-2 (encoded by PTPN11) signifi-
cantly diminished PDGFR-alpha-promoted tumorigenesis in vitro and
in vivo. Furthermore, the inhibition of SHP-2 by shRNAs or inhibitors
disrupted the interaction of PI3K with PDGFR-alpha, suppressed Akt acti-
vation, and impaired tumorigenesis of Ink4a/Arf-null cells. Additionally,
SHP-2 inhibition attenuated mammalian target of rapamycin (mTOR)
activation of S6 kinase, and the inhibition of mTOR abrogated
PDGFR-alpha-promoted tumorigenesis. Taken together, our data suggest
that in proneural glioblastomas with Ink4a/Arf deficiency, PDGFR-alpha
promotes tumorigenesis through the PI3K/Akt/mTOR-mediated pathway
regulated by SHP-2 activity. These findings not only functionally validate
the genomic analysis of proneural glioblastomas with PDGFR-alpha over-
expression but also identify SHP-2 as a potential target for treatments
against malignant glioblastomas.
CB-17. TARGETING POLO-LIKE KINASE 1 (PLK1) FOR
TREATMENT OF PEDIATRIC BRAIN CANCERS
Cathy Y. Lee , Abbas Fotovati , and Sandra E. Dunn ; Child and Family
Research Institute
Brain tumors are the leading cause of cancer death in children. Pediatric
brain cancer is extremely aggressive, is difficult to treat, and has high mor-
tality/morbidity rates. Drug resistance and disease relapse are two major chal-
lenges to long-term survival. Thus, there is an immediate need to investigate
novel therapeutic strategies that improve patient outcome. In a genome-wide
siRNA library screen of 691 kinases, we recently identified polo-like kinase
1 (PLK1) a lead target; silencing PLK1 resulted in 80%-90% growth suppres-
sion in pediatric rhabdomyosarcoma cells. Further target validations revealed
that PLK1 inhibition by siRNA and small molecular inhibitor BI2636 signifi-
cantly inhibited cell growth, caused G2/M arrest, and induced apoptosis in
pediatric glioblastoma multiforme (GBM) and medulloblastoma cell lines
(IC50¼ 5 nM). Of note, PLK1 inhibition is cytotoxic to the GBM cell line
SF188, which is notably TMZ-resistant, suggesting that this kinase may be
a potential molecular target for the treatment of TMZ-refractory brain
tumors. Further, we are examining the possibility that PLK1 inhibition has
the potential to eliminate brain tumor-initiating cells (BTICs). We have pre-
liminary results indicating that the level of activated PLK1 is much higher in
neurospheres than in cells in monolayer. Importantly, BI2536 inhibited neuro-
sphere growth by as much as 90% in 7-day cultures, where the number and
size of the spheres were affected. Given that clinical trials have already
begun to address the promise of BI2536 in adult cancers, we propose that it
may also be considered for the treatment of pediatric brain tumors, particu-
larly for those that are TMZ-resistant.
CB-18. EFFECTS OF BONE ENVIRONMENT ON MENINGIOMA
BIOLOGY
Martin A. Proescholdt , Eva-Maria Störr , Annette Lohmeier , and
Alexander Brawanski ; University Regensburg Medical Center
PURPOSE: Meningiomas are considered benign tumors, and in the
majority of cases, complete surgical resection will be curative. However,
invasion of the adjacent bone is a known risk factor for recurrence. We
hypothesized that the bone environment contributes to a more aggressive be-
havior in meningiomas. We therefore exposed meningioma cells cultured
from resected tumor tissue to bone-specific factors and observed the cells’
growth rate, bone invasiveness, and susceptibility to hydroxyurea (HU) treat-
ment. METHODS: Meningioma cell culture was established from 21 surgi-
cal meningioma specimens. The purity of the cultures was defined by
immunofluorescent staining for epithelial membrane antigen (EMA), vimen-
tin, and GFAP. The cells were treated with IGF I IGFII at a concentration of
100 ng/mL, TGF beta 1 and TGF beta 2 at 10 ng/mL, and extracellular
calcium concentration of 2, 4, and 8 mmol/L. Cell growth rate was analyzed
by a colorimetric cell proliferation assay. Bone invasion was analyzed by
co-cultivation of meningioma cells with neonatal mouse calvariae. The
invading cells were visualized with immunofluorescent staining for human
HLA and quantified by cell count. HU treatment was performed at
100 mmol/L, Apoptotic cell death was analyzed via TUNEL assay.
RESULTS: Immunofluorescent staining showed a 98% purity of the cultures.
Treatment with increasing extracellular calcium concentrations and IGF I
and IGFII induced a significant increase in cell proliferation, whereas TGF
beta 1 and TGF beta 2 had no proliferative effects. Bone invasion was signifi-
cantly enhanced in all treatment groups compared with controls. All bone-
specific growth factors significantly diminished the induction of apoptotic
cell death by HU. CONCLUSION: Our data show that that the bone
environment can induce cell proliferation, enhanced bone invasion, and
resistance to HU treatment in meningioma cells. This suggests that the
bone matrix provides a permissive environment for a more aggressive bio-
logical phenotype in meningiomas.
CB-19. EGFRVIII PROMOTES GLIOMA INVASION THROUGH
SRC-DEPENDENT PHOSPHORYLATION OF DOCK180Y722
AND STIMULATES RAC1 ACTIVITIES
Bo Hu 1, Haizhong Feng 1, Michael J. Jarzynka 1, Kunwei Liu 1, Kodi
S. Ravichandran 2, Kritina Vuori 3, Careen Tang 4, Ryo Nshikawa 5, Treence
G. Johns 6, Frank B. Furnari 7, Webster K. Cavenee 7, and Shiyuan Cheng 1;
1University of Pittsburgh; 2University of Virginia; 3Burhman Institute for
Medical Research; 4Georgetown University; 5Saitama Medical University;
6Monash Institute for Cancer Research; 7University of California
Acquisition of insidiously invasive behaviors by malignant glioblastoma
cells involves the aberrant activations of signal pathways via multiple
genetic alterations, including mutation of the epidermal growth factor recep-
tor (EGFR). EGFRvIII, a constitutively activated EGFR mutant, is the most
commonly occurring and amplified mutant form of EGFR in glioblastomas.
We recently reported that Dock180 and ELMO1, a bipartite Rac1 guanidine
nucleotide exchange factor (GEF), promotes glioma cell invasion. We ident-
ify a regulatory mechanism by which EGFRvIII promotes glioma cell inva-
sion through phosphorylation of Dock180-stimulating Rac1 activities.
Exogenously expressed EGFRvIII significantly promotes SNB19 and
LN444 glioma cell migration in vitro and tumor growth and invasion in
the brains of animals. EGFRvIII induces an Src-mediated phosphorylation
of Dock180 at tyrosine residue Y722 and stimulates Rac1 activities.
Inhibition of Src by pharmaceutical inhibitors or a dominant negative Src
mutant abrogates EGFRvIII-induced p-Dock180Y722, whereas a constitu-
tively activated Src induces p-Dock180Y722 without EGFRvIII stimulation.
In vitro, cellular depletion of Dock180 or expression of a Dock180Y722F
mutant inhibits EGFRvIII-promoted glioma cell growth and invasion
activating Rac1, whereas wild-type Dock180 markedly enhances
EGFRvIII-promoted tumor growth and invasion in the brain. A homologous
search revealed that Y722 is highly conserved in Dock180 proteins among
various species. Significantly, when primary human glioblastoma specimens
were analyzed by immunohistochemical staining using specific antibodies
against EGFRvIII and p-Dock180Y722, p-Dock180Y722 was found to be
co-over-expressed with EGFRvIII in the invasive areas but not the central
regions of glioblastoma specimens. Taken together, these data indicate
that EGFRvIII induces glioma cell invasion through Src-dependent
p-Dock180Y722 and stimulates Rac1 activity, suggesting that the aberrant
activation of p-Dock180Y722-Rac1 could be an alternative therapeutic
target in the treatment of glioblastomas.
CB-20. NEDD9 IS REQUIRED FOR MESENCHYMAL INVASION
OF GLIOBLASTOMA CELLS
Jessie Zhong and Geraldine M. O’Neill ; Kids Research Institute, Children’s
Hospital at Westmead; Discipline of Paediatrics and Child Health,
University of Sydney
RATIONALE: Glioblastoma is the most common primary brain tumor,
with an average patient survival of 12–15 months. Despite advances in tech-
nology and therapies over the last two decades, there has been little improve-
ment in survival, and the final mortality rate remains at almost 100%.
Therefore, there is an urgent need to develop new drugs to target specific
molecules in signaling pathways that have been implicated in glioblastoma.
Abstracts













Individual glioblastoma cells are able to diffusely infiltrate into surrounding
healthy brain tissue, leading to recurrence of the tumor and ultimately death.
Thus, targeting migration signaling molecules may prove promising. An
exciting candidate molecule is NEDD9 (neural precursor cell expressed,
developmentally down-regulated 9). The docking molecule NEDD9/
HEF1/Cas-L is an in vivo regulator of cell migration, has been linked to metas-
tasis of melanoma and lung cancer, and has recently been demonstrated to
promote migration in glioblastoma cells. OBJECTIVE: The aim of this
study was to investigate the role of NEDD9 in glioblastoma cell migration
using three-dimensional (3D) culture systems to better recapitulate the in
vivo microenvironment. METHODS AND RESULTS: We screened seven
human glioblastoma cell lines and observed high-level NEDD9 expression in
half the cell lines, correlating with mRNA levels as determined by quantitative
real-time polymerase chain reaction (PCR). We also established a 3D-collagen
gel model that revealed distinct morphological differences when compared
with cells on 2D substrates. Subsequently, siRNA targeting of NEDD9 was
shown to cause an 80% decrease in NEDD9 expression in 3 high-expressing
cell lines, and siRNA-mediated down-regulation of NEDD9 significantly
inhibited glioblastoma cell migration and invasion in 3D collagen gels.
CONCLUSIONS: Our data are the first demonstration that NEDD9 plays a
role in the 3D invasion of glioblastoma cells.
CB-21. CIRCULATING TUMOR CELLS (CTCS) IN PATIENTS
WITH GLIOBLASTOMA MULTIFORME (GBM)
Loic P. Deleyrolle , Maryam Rahman , Erin M. Dunbar , Maria A. Caldeira ,
and Brent A. Reynolds ; University of Florida
INTRODUCTION: Expanding evidence from circulating tumor cells
(CTCs) in numerous solid tumors, including glioblastoma multiforme
(GBM), has led to techniques that isolate and characterize these cells from
peripheral blood. We hypothesized that GBM CTCs would be detectable
and distinguishable from normal blood cells using a cluster of differentiation
(CD) antibody panel and fluorescence activated cell sorting (FACS). Once
isolated, these cells would be characterized for cell signaling and genetic
abnormalities. METHODS: Under IRB approval, GBM cell lines were
screened with 100 CD antibodies. The antibodies that had positive
expression (.90% cells) or low expression (,10% of cells) were then
used to screen normal peripheral white blood cells (WBC) from control sub-
jects. The resulting CD antibody panel was then used to detect CTCs in the
peripheral blood of GBM patients using FACS. RESULTS: Following the
screening process, the CD antibody panel consisted of CD45 (negative in
GBM, positive in WBC), CD8 (negative in GBM, positive in WBC), CD81
(positive in GBM, negative in WBC), and CD63 or CD56 (positive in
GBM, negative in WBC). Testing the ability of this panel to isolate GBM
cells mixed with WBC, a subpopulation (CD82/CD452/CD81+/
CD56+/CD63+) was found only in the mix of cells and not in the WBC
alone. The CD antibody panel was then used to test for CTCs in the periph-
eral blood of GBM patients. A distinct population of putative GBM cells was
identified, representing ,1% of the total number of cells. We have used this
strategy to isolate CTCs in three GBM patients. These cells have not been
seen in six control samples. Currently, additional GBM CTCs are being
characterized with cell culture and PCR and correlated clinically.
CONCLUSION: GBM CTCs exist and can be isolated and characterized
from the peripheral blood of GBM patients.
CB-22. BREAKING HYPOXIA ADAPTATION AND BLOCKING
GLIOMA CELL GROWTH BY INHIBITING AMP KINASE
ACTIVITY
Xiaona Liu , Sara Yacyshyn , and Biplab Dasgupta ; Cincinnati Children’s
Hospital Medical Center
INTRODUCTION: During the course of evolution of GBMs, glioma cells,
particularly glioma initiating/stem cells (GICs) become adapted to hypoxic
growth. These cells are resistant to ionizing radiation and chemotherapy,
and the volume and intensity of hypoxia in GBM before radiotherapy are
strongly associated with poorer time-to-progress and survival. Thus, there
is a need to develop new treatment strategies to target the hypoxia addiction
of glioma cells and especially GICs. AMP activated protein kinase (AMPK) is
a cellular energy sensor that plays a critical role in angiogenesis, cell survival
in response to hypoxic stress, genotoxic stress (DNA damaging/alkylating
agents), as well as in response to radiation. There is tremendous conflict
regarding the role AMPK in cancer. Here we test our hypothesis that
AMPK inhibition as a single agent or in combination therapy will inhibit
GIC maintenance and significantly reduce or prevent glioma growth and
recurrence. METHODS: We initially monitored the growth and migration
of three human glioma cell lines in the presence or absence of
pharmacological and genetic activation or inhibition of AMPK under
normoxic and hypoxic growth. RESULTS: Our initial studies unequivocally
demonstrated that (i) compared to normal astrocytes, glioma cells express
significantly higher levels of active AMPK, (ii) two AMPK-activating
agents have opposite effects during the hypoxic growth of glioma cells,
suggesting different mechanisms of action of these compounds, (iii) these
agents have little effect on glioma cell motility, (iv) pharmacological or
genetic inhibition of AMPK significantly blocks glioma cell growth, an
effect that is compounded during hypoxia, and (v) pharmacological inhi-
bition of AMPK completely blocks glioma cell motility. CONCLUSION:
Our initial results demonstrate convincingly that blocking AMPK during
hypoxic growth prevents glioma cell proliferation and migration, and inhi-
biting this energy-sensing pathway in combination with radiotherapy and
chemotherapy could potentially block glioma growth and recurrence.
CB-23. EXPRESSION OF SRC FAMILY KINASES IN GLIOMA
STEM CELLS AND THEIR ROLE IN CELL PROLIFERATION AND
MIGRATION
XiaosiHan , XiuhuaYang , Crystal G.Wheeler , NataliaFilippova , Catherine
P. Langford , Qiang Ding , Hassan M. Fathallah , George Y. Gillespie , and
Louis B. Nabors ; University of Alabama at Birmingham
Src family kinases (SFKs) are highly expressed and active in clinical glio-
blastoma multiforme specimens. SFKs inhibitors have been demonstrated
to inhibit proliferation, migration, and invasion of primary glioma cells
and are currently in clinical trials for the treatment of glioblastoma.
However, the expression of SFKs and their functional role in glioma stem
cells (GSC) are unclear. We examined the expression pattern of individual
members of SFKs in several CD133+ glioma stem cells as well as their cor-
responding (CD133-) primary glioma cells isolated from the same human
glioblastoma xenografts. We found that the SFKs were highly expressed
and activated in glioma stem cell lines, and the expression pattern of individ-
ual kinase members may or may not have been similar to that of their corre-
sponding primary glioma cells. Members of SFKs expressed in GSC include
Fyn, c-Src, c-Yes, Lck, and Lyn. The SFK inhibitor dasatinib had little effect
on the growth of glioma stem cells, although it effectively inhibited the
proliferation of primary glioma cell lines at a concentration comparable
to that of clinical therapeutic serum levels. However, SFK inhibition by
dasatinib significantly suppressed the migration of glioma stem cells in a
laminin-coated Transwell migration assay. These results suggest that an
SFK inhibitor alone is unlikely to completely control tumor growth, and
combination with other medications will be needed for the effective inhi-
bition of cancer stem cells. (This work was supported in part by NCI
Grants 3P30CA013148-38S5, P50CA097247-05S4.)
CB-24. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2
(IGFBP2) PROMOTES GROWTH OF MEDULLOBLASTOMA
CELL LINES
Tom B. Davidson , Filipp Gortalum , Lingyun Ji , Kelly Engell ,
RichardSposto , ShahabAsgharzadeh , and AnatErdreich-Epstein ; Children’s
Hospital Los Angeles
The insulin-like growth factor (IGF) signaling pathway has an important
role in proliferation in many tissues and a variety of tumors. The effects of
IGF on tumorigenesis are partly modulated by the six secreted IGF-binding
proteins (IGFBPs). Circulating IGFBPs can be inhibitory by reducing avail-
able free IGFs or may enhance the action of an IGF by increasing ligand pres-
entation to its receptor. Additionally, in some cases, IGFBP2 is also thought
to utilize IGF1R-independent mechanisms, although these mechanisms are
mostly unknown. Of clinical relevance, IGFBP2 overexpression is observed
in many neoplasms and is associated with a more malignant state in prostate
cancer, breast cancer, colon cancer, leukemia, and gliomas. In this project,
we are working to understand the function of IGFBP2 in medulloblastoma,
the most common malignant brain tumor in children. Microarray analysis
(U133 plus 2) revealed an 85.8-fold overexpression of IGFBP2 in 31
patient medulloblastoma tissue samples when compared to 13 normal
cerebella samples and a mean overexpression of 16.5-fold in four medullo-
blastoma cell lines. Immunohistochemistry of 7/7 of these samples demon-
strated high IGFBP2 expression (nuclear, intra-, and extra-cellular), while
in normal cerebellum, IGFBP2 expression was limited to a small population
of pericytes. Addition of human recombinant IGFBP2 (1–10 ng/mL, 72
hours) in the presence of 0.5% fetal bovine serum to two medulloblastoma
cell lines increased cell number as measured by MTT by 75%–100% for
CHLA-259 (n ¼ 10 per experiment in two separate experiments with p ,
0.001 in each) and by 35%–50% for D283MED (n ¼ 10 per experiment
in three separate experiments with p , 0.001). However, IGFBP2 did not
affect phosphorylation of two of the IGF-receptor downstream targets,
AKT (ser473) and ERK, suggesting possible IGF-independent effect(s) of
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IGFBP2 in these medulloblastoma cell lines. Through ongoing work, we are
now seeking to understand the mechanism of the growth-promoting effect of
IGFBP2 in medulloblastoma cell lines.
CB-25. INVESTIGATING THE ROLE OF NEUROTROPHIN
SIGNALING IN BRAIN TUMOR STEM CELLS
Samuel O.Lawn , SamWeiss , DonnaSenger , and PeterForsyth ; University of
Calgary
Glioblastoma multiforme (GBM) is a highly invasive disease that is refrac-
tory to current treatments. The cancer stem cell hypothesis states that tumor
growth is driven and maintained by a rare subset of self-renewing cells that
are highly tumorigenic and capable of differentiation. Understanding the
biology of these cells could aid the development of therapies designed to
eliminate them, either through conventional inhibition of key growth and
survival factors or through more novel approaches, such as the promotion
of BTSC differentiation. Previous work by this lab has identified and charac-
terized the role of the neurotrophin receptor p75NTR in promoting glioma
cell invasion and shown that this function of p75NTR is sensitive to treatment
with gamma-secretase inhibitors (GSIs). It was also demonstrated that
p75NTR is expressed in brain tumor stem cells (BTSCs). The role of
p75NTR and other neurotrophin receptors in BTSCs is being further investi-
gated by means of in vitro and in vivo functional studies (e.g. tumorigenicity,
differentiation potential, and invasion) following lentiviral shRNA knock-
down of receptor expression, the pharmacological inhibition of receptor
function, and the application of relevant receptor ligands. It is hoped that
these specific methods of p75NTR manipulation will help discriminate the
relative contribution of GSI-mediated targeting of p75NTR in the context
of inhibiting other gamma-secretase targets, such as Notch.
CB-26. ANALYSIS OF PHOSPHOTYROSINE SIGNALING IN
GLIOBLASTOMA IMPLICATES NUCLEAR EGFRVIII-STAT5B
COMPLEX IN THE INDUCTION OF BCL-XL EXPRESSION
Khatri Latha 1, Vaibhav Chumbalkar 1, Ming Li 2, Anupama Gururaj 1,
YeoHyeon Hwang 1, Rebecca Maywald 1, Sumana Dakeng 1, Lixia Dao 1,
Keith Baggerly 1, Raymond Sawaya 1, Kenneth Aldape 1, Webster Cavenee 2,
FrankFurnari 2, and OliverBogler 1; 1The University of Texas MD Anderson
Cancer Center; 2Ludwig Institute for Cancer Research
Aberrant EGFR signaling is a major contributing force to glioma pro-
gression and treatment resistance. The most prevalent mutation, DEGFR/
EGFRvIII, is an inframe deletion of the extracellular domain, occurring in
the about 40% of glioblastomas and promoting growth and survival of
tumor cells. The signaling of DEGFR is ligand-independent, does not
involve receptor dimerization, and is of low intensity. We have analyzed
DEGFR signaling using shotgun phosphoproteomics based on recovery of
phosphotyrosine-containing peptides and mass spectrometry. Two glioma
cell lines expressing DEGFR and wild-type EGFR and with different PTEN
backgrounds were compared by this approach, leading to the identification
of 249 tyrosine phosphorylated proteins. Of these, 30 showed statistically
significant differences in intensity when DEGFR was present, including the
previously described Gab1 and c-Met, and a newly identified phosphoryl-
ation of STAT5b on Y699 in cells expressing DEGFR. In human glioblas-
toma samples, pSTAT5 levels correlated positively with EGFR expression
and were associated with reduced survival. Phosphorylated STAT5b and
DEGFR associated in the nucleus, bound DNA, and were found on promo-
ters known to be regulated by STAT5, including that of the Aurora A gene,
which they positively regulated. Interestingly, the activation of STAT5b
downstream of DEGFR was dependent on Src, in contrast to the signal
from EGF stimulated EGFR to STAT5b, which showed the involvement of
Jak2. DEGFR cooperated with STAT5b to positively regulate the Bcl-XL
promoter, and knockdown of STAT5b suppressed anchorage- independent
growth, reduced the levels of Bcl-XL, and sensitized glioblastoma cells to
cisplatin. Taken together, these observations support the conclusion that
the nuclear association of DEGFR with STAT5b promotes oncogenesis and
treatment resistance in glioblastoma via up-regulation of Bcl-XL.
CB-27. FORCED DIMERIZATION AMPLIFIES EGFRVIII
SIGNALING AND INCREASES ITS ONCOGENICITY
YeoHyeonHwang , Vaibhav Chumbalkar , KhatriLatha , and OliverBogler ;
The University of Texas MD Anderson Cancer Center
Glioblastoma multiforme (GBM) is the most common and lethal primary
human brain tumor. GBMs are characterized by a variety of genetic
alterations, amongst which oncogenic mutations of the epidermal growth
factor receptor (EGFRvIII/DEGFR) are most common. GBMs harboring
EGFRvIII have increased proliferation and invasive characteristics versus
those expressing wild-type (wt) EGFR. The signaling of EGFRvIII is
ligand-independent and does not involve receptor dimerization and as a
result is low intensity, which allows EGFRvIII to evade the normal mechan-
isms of internalization and degradation by the endocytic machinery; hence,
its signaling is persistent. This low intensity signal has made it challenging
to uncover whether there are components of EGFRvIII signaling that are dis-
tinct from wild-type EGFR signaling. We have created a chimeric chEGFRvIII
that can be dimerized experimentally using a variant FKBP12 domain and
cognate small molecule, a process termed chemically induced dimerization
(CID). CID increases chEGFRvIII activity and phosphorylation of down-
stream targets to levels comparable to acutely EGF-stimluated EGFR.
Interestingly, increased activity of EGFRvIII did not promote receptor intern-
alization, suggesting that the failure of EGFRvIII to enter endocytosis is
inherent in its structure. Mice bearing U87 cells expressing chEGFRvIII intra-
cranially died sooner when treated with CID, suggesting that forced dimeriza-
tion enhanced the oncogenic signal. Phosphoproteomic analysis of the
enhanced EGFRvIII signal using mass spectrometry will be presented.
CB-28. ACCESS TO THE NUCLEUS IS REQUIRED FOR THE FULL
ONCOGENIC POTENTIAL OF EGFRVIII
AnupamaGururaj and OliverBogler ; The University of Texas MD Anderson
Cancer Center
RATIONALE: A key molecular characteristic in a subset of glioblastoma is
over-expression, amplification, and mutation of EGFR. The most common
mutant is EGFRvIII, with a large intragenic deletion of the extracellular
domain, leading to constitutive activation. GBMs expressing aberrations in
EGFR have a more aggressive biological and clinical behavior. Nuclear trans-
location of EGFR has been reported in cancers of the breast, esophagus,
bladder, and thyroid and is correlated with disease progression in these
tumors. We hypothesize that nuclear EGFR and EGFRvIII occurs in GBM,
and we are interested in defining the role of nuclear EGFRvIII in oncogenic
functions. APPROACH: Biochemistry and microscopy were used to character-
ize the occurrence of nuclear EGFRvIII. Site-directed mutants that restrict
EGFR to either the nucleus or the cytoplasm were used in cell-based proteomic
and xenograft studies to define nuclear functions of EGFRvIII. RESULTS:
Preliminary studies have revealed that a fraction of EGFRvIII is consistently
in the nucleus in glioma cell lines. Stable cell lines overexpressing EGFRvIII
mutants that restrict EGFRvIII to either the nucleus (mutated nuclear export
sequence) or the cytoplasm (mutated nuclear localization sequence) show
that increasing EGFRvIII in the nucleus increases oncogenicity while
cytoplasmic enrichment decreases its oncogenicity as measured by ancho-
rage-independent growth and intracranial xenograft. In order to address the
role of EGFR in the nucleus, we plan to carry out phospho-proteomic and
mass spectrometric analyses in order to determine specific binding partners/
substrates of nuclear EGFRvIII and to identify the phospho-sites of
EGFRvIII that are involved in nuclear translocation. Other aims of the study
are to look for correlations between nuclear EGFR and glioma progression,
prognosis, recurrence, and resistance to treatment.
CB-29. PHOSPHOPROTEOMIC ANALYSIS OF NOVEL JAK/STAT
INHIBITORS IN GLIOMA CELLS
Vaibhav Chumbalkar , Jaykumar Arumugam , Lixia Dao , Keith Baggerly ,
WaldemarPriebe , and OliverBogler ; The University of Texas MD Anderson
Cancer Center
INTRODUCTION: Signal transducer and activator of transcription
(STAT) molecules are constitutively activated in many cancers, including
gliomas. Targeting STATs is a promising therapeutic approach, and
WP1066 and WP1193 are small molecule inhibitors of the JAK/STAT
pathway that have shown potential in preclinical studies. Here we used
phosphotyrosine-directed shotgun phosphoproteomics to profile the impact
of WP1066 and WP1193 on glioma cell signaling. APPROACH: LNZ308
glioma cells were treated with WP1066 and WP1193, followed by peptide
extraction and enrichment of phosphotyrosine peptides by immunoaffinity
using P-TYR-100 antibody. These peptides were further enriched on tita-
nium dioxide resin on a special nano-fluidics chip (Phosphochip, Agilent
Technologies) and analyzed on an ETD-enabled ion trap mass spectrometer.
After identifying the phosphopeptides with Spectrum Mill software from
resultant spectra, these phosphopetides were quantified based on their inten-
sities. Pathway analysis was performed to integrate the findings. RESULTS:
We identified and quantified 256 phosphotyrosine peptides from 99 proteins.
We observed a significant change in intensity for 20 (for WP1066) and 16
(for WP1193) proteins. As expected, levels of STAT3 phosphopeptide
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Y705 were reduced in drug-treated samples. We also observed an increase in
ERK2 phosphorylation, which was confirmed by Western blot. Proteins
whose phosphorylation changed significantly included kinases such as
ERK, CDC2, GSK3alpha, HCK-1, FAK, and transporter molecules includ-
ing Connexin 43 and Solute carrier family 38 proteins. SIGNIFICANCE:
This analysis confirmed that WP1066 and WP1193 suppress the activity of
the known targets, Jaks, in glioma cells. In addition, we found changes in
pathways not directly associated with Jak signaling, such as the ERKs,
which may help us understand potential failures or limitations of drug
therapy. Further investigations of such phosphorylation changes will help
us design smart combinations and anticipate and monitor treatment failures.
CB-30. CLEAVAGE OF THE BRAIN-SPECIFIC PROTEIN
BREVICAN RELEASES A FRAGMENT THAT PROMOTES
EGFR-DEPENDENT GLIOMA CELL MOTILITY
Hosung Sim , Colleen A. Pineda , Yang Pan , Bin Hu , and Mariano
S. Viapiano ; The Ohio State University
A fundamental challenge in treating malignant gliomas is their distinctive
ability to infiltrate normal neural tissue, which makes them virtually impossible
to eliminate by conventional therapies. Understanding the mechanisms of
glioma invasion is essential to designing more effective treatments against
tumor recurrence. Brevican, a predominant brain-specific proteoglycan, is a
major component of the neural extracellular matrix (ECM) that restricts the
motility of normal neural cells. Surprisingly, brevican is upregulated in
gliomas, is expressed in the invasive border of these tumors, and promotes
glioma dispersion. Thus, our goal was to determine the molecular mechanisms
underlying this uncommon role of brevican in gliomas. Glioma cells were
engineered to express truncated or mutated versions of brevican and analyzed
for effects on adhesion, migration, and dispersion in organotypic cultures. Cells
were also exposed to brevican and truncated brevican to identify potential sig-
naling pathways activated by the proteoglycan. In addition, a biotin-acceptor
“Bir” sequence (13aa) was inserted at the N-terminus of brevican to create con-
structs that could be biotinylated and directly purified from the conditioned
medium of engineered HEK293 cells. Analysis of receptor tyrosine kinase sig-
naling showed that brevican was unable to enhance cell migration, but cleavage
of this protein by ADAMTS proteases yielded an N-terminal fragment that
activated EGFR and Erk1/2, leading to fibronectin recruitment to the cell
surface and increased cell adhesion and migration. Brevican effects on EGFR
activation and cell adhesion were mediated by Src kinases and therefore inhib-
ited with a pan-Src kinase inhibitor, suggesting a transactivating effect of
N-terminal brevican on EGFR signaling. Together, these results suggest that
the N-terminal fragment of brevican, which is highly increased in gliomas,
acts as a paracrine ligand that promotes glioma cell motility. This is the first
molecular approach revealing potential mechanisms underlying the conversion
of inhibitory neural proteoglycans into pro-invasive signals in gliomas.
CB-31. IDENTIFYING MODIFIER GENES OF MPNSTS IN THE
NF1;P53CIS MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 1
Jessica A.Van Schaick 1, KeikoAkagi 2, SandraBurkett 1, ChristinaDiFabio 1,
Robert Tuskan 1, Jessica Walrath 1, and Karlyne Reilly 1; 1NCI; 2The Ohio
State University
The current study aimed to identify modifier genes of malignant peripheral
nerve sheath tumors (MPNSTs) in the Nf1;p53cis (NPcis) mouse model of
NF1. Previous studies have shown that the incidence of MPNST develop-
ment in the NPcis mouse model is affected by the parental transmission of
the mutant chromosome 11. In this study, microarray analysis was used to
examine gene expression differences between MPNST primary tumors
derived from NPcis mice varying in inheritance of the NPcis chromosome
from the mother (NPcis maternal) or father (NPcis paternal). Grb10 was
found to be more highly expressed in NPcis maternal MPNSTs. Zrsr1 was
found to be more highly expressed in NPcis paternal MPNSTs. qPCR was
used to validate both gene expression differences. We chose to focus first
on Grb10 due to its role as a cytoplasmic signaling adapter protein.
Fluorescence in situ hybridization was used to examine the presence of
Grb10 on chromosome 11. Grb10 was found to be lost more frequently in
NPcis paternal MPNST cell lines, potentially contributing to the decrease
in Grb10 gene expression seen in these tumors. Grb10 is paternally
imprinted in the periphery of the mouse; therefore, we examined Grb10
isoform expression and found paternal and maternal isoforms expressed in
the MPNSTs. Due to these results, we are examining whether loss of imprint-
ing is contributing to tumorigenesis. In order to study the function of Grb10
in vitro, more than 200 clones of Grb10 isoforms were sequenced from the
NPcis MPNSTs, and several new isoforms were identified. Finally, we have
generated NPcis;Grb10cis mutant mice. Preliminary studies indicate that
NPcis;Grb10cis mice have an increase in tumor volume and a decrease in
survival. Additionally NPcis;Grb10cis maternal mice have an increase in
MPNST incidence. Our studies indicate that Grb10 is a candidate modifier
gene of MPNSTs, acting in a growth-suppressive manner.
CB-32. FOXM1 IS REGULATED BY HSF1 AND PROTECTS
GLIOMA CELLS FROM HEAT SHOCK STRESS-INDUCED CELL
DEATH
Bingbing Dai , Zhitao Jing , Shin-Hyuk Kang , Dawei Li , Keping Xie , and
Suyun Huang ; The University of Texas MD Anderson Cancer Center
The forkhead box M1 (FoxM1) is a key transcription factor regulating
multiple cell cycle-related genes that control G1-S and G2-M phase pro-
gression. Our previous studies have shown that FoxM1 is over-expressed
in human brain tumors and other solid tumors and is correlated with
cancer progression and invasion. Knocking down FoxM1 inhibited cancer
cell growth in vitro and brain tumor formation in vivo. However, how
FoxM1 is regulated in either normal or malignant cells still is not clear. In
this study, our results showed that FoxM1 was up-regulated by heat shock
factor 1 (HSF1) during heat shock stress conditions. Knocking down HSF1
with HSF1 siRNA or inhibiting HSF1 with an HSF1 inhibitor abrogated
heat shock-induced expression of FoxM1. Similarly, heat shock stress did
not induce FoxM1 expression in mouse embryo fibroblast cells with Hsf1
knockout (MEF hsf1 2/2). Chromatin immuno-precipitation assay and
promoter reporter assay confirmed that HSF1 directly binds to the FoxM1
promoter. Furthermore, our results demonstrated that FoxM1 is required
for the G2-M phase progression through regulating cyclinB1, CDC25B,
and CDC2 in a mild heat shock stress condition while enhancing cell survival
during lethal heat shock stress. Finally, immunohistochemical analysis of 34
human glioblastoma specimens also showed a significant correlation
between FoxM1 overexpression and elevated HSF1 expression. Our results
indicated that FoxM1 is critical for HSF1-mediated heat shock response,
which increases cell survival and protects cells from stress-induced cell death.
CB-33. MITOCHONDRIAL LON IS THE FIRST IDENTIFIED
MITOCHONDRIAL PROTEIN TO MEDIATE HYPOXIC
ADAPTATION, INVASION, AND TREATMENT RESISTANCE TO
RADIATION AND TEMOZOLOMIDE IN MALIGNANT GLIOMA
CELL LINES
Xing Gong , Yen Vuong , and Daniela A. Bota ; UC Irvine
BACKGROUND: Malignant gliomas are characterized by extensive hypoxic
areas and innate resistance to treatment. Hypoxia-inducible factor HIF 1-a is an
indicator of malignant angiogenesis and abnormal proliferation, but less studied
is HIF1-a involvement in the metabolic shift to glycolysis required for survival
in low-oxygen environments. One of the HIF 1-a regulated genes is the mito-
chondrial Lon, which plays an important role in mitochondrial bioenergetics
and mitochondrial DNA maintenance. Here, we demonstrate that Lon controls
metabolic adaptation to hypoxia in glioma cells in direct response to HIF1-a
activation. Also, Lon induction is used by glioma cells to increase resistance
to radiation and chemotherapy by direct repair of mitochondrial DNA.
RESULTS: Two malignant glioma cell lines (D-54-MG and U-251-MG) were
exposed to hypoxia, which increased HIF1-a protein levels. The increase of
HIF1-a levels was paralleled by a doubling in both the mRNA and the
protein Lon levels, while HIF 1-a down-regulation was associated with a
brisk decrease of Lon expression. Lon protease up-regulation in D54-MG
cells caused increased invasion and resistance to starvation. Treatment with
temozolomide (TMZ) led to a four-fold induction of Lon, while Lon down-
regulation led to increased sensitivity to TMZ. TMZ-resistant lines D54-TR
and U251-TR had twice the level of Lon of their parent TMZ-sensitive lines.
Lon protease in the D54-MG cells induced resistance to TMZ at levels
similar to that of the resistant line D54-TR. D54 cells with Lon over-expression
also had increased resistance to radiation. Both the radiation and TMZ resist-
ance in the D54 MG/Lon over-expression cells was caused by an increase in
the repair of the treatment-induced mitochondrial DNA damage.
CONCLUSIONS: The data presented show that Lon is one of the principal
mediators connecting hypoxia with invasion, resistance to starvation,
chemo-resistance, and radio-resistance, supporting our current research of
Lon inhibition as a possible therapeutic target in malignant gliomas.
CB-34. THE GLIOMA ONCOPROTEIN BCL2L12 INHIBITS THE
P53 TUMOR SUPPRESSOR
Alexander H. Stegh ; Northwestern University
Glioblastoma multiforme (GBM) is a highly lethal and neurologically
debilitating brain tumor characterized by intense apoptosis resistance and
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extensive necrosis. Bcl2L12 (for Bcl2-Like 12) is a cytoplasmic and nuclear
protein that is consistently over-expressed in primary GBM and functions
to inhibit post-mitochondrial apoptosis signaling at the level of effector cas-
pases by directly binding and blocking caspase-7 maturation (Stegh et al.,
Genes Dev. 21:98–111) and by up-regulating alpha-B-crystallin expression
to inhibit caspase-3 activation (Stegh et al., PNAS 105:10703–10708). In
the course of studying Bcl2L12’s nuclear functions, we determined that
nucleoplasmic Bcl2L12 co-localizes and physically interacts with p53
tumor suppressor protein as evidenced by the capacity of Bcl2L12 to (i)
enable bypass of replicative senescence without concomitant loss of p53 or
p19Arf, (ii) inhibit p53-dependent DNA damage-induced apoptosis, (iii)
abrogate p53 binding to its target gene promoters, and (iv) block endogenous
p53-directed transcriptomic changes following genotoxic stress.
Correspondingly, TCGA profile and tissue protein analyses of human
GBM specimens show significantly lower Bcl2L12 expression in the setting
of genetic p53 pathway inactivation. Thus, Bcl2L12 is a multi-functional
protein that contributes to intense therapeutic resistance of GBM through
its ability to operate on two key nodes of cytoplasmic and nuclear signaling
cascades.
CB-35. TUMOR HETEROGENEITY IS AN ACTIVE PROCESS
DRIVEN BY A MUTANT EGFR-INDUCED PARACRINE CIRCUIT
IN GLIOBLASTOMA
Frank Furnari 1, Maria-del-Mar Inda 1, Rudy Bonavia 1, Akitake Mukasa 2,
Yoshitake Narita 3, Dinak Sah 4, Scott Vandenberg 5, Cameron Brennan 6,
Terrance Johns 7, Robert Bachoo 8, Philip Hadwiger 9, Pamela Tan 1,
Pamela Tan 9, Ronald DePinho 10, and Webster Cavenee 1; 1Ludwig
Institute-UCSD; 2The University of Tokyo; 3National Cancer Center
Hospital; 4Alnylam Pharamceuticals, Inc.; 5University of California, San
Diego; 6Memorial Sloan-Kettering Cancer Center; 7Monash Institute of
Medical Research; 8University of Texas Southwestern Medical Center;
9Alnylam Europe AG; 10Dana-Farber Cancer Institute
A powerful oncogenic event in GBM is the amplification and rearrange-
ment of EGFR (EGFRvIII, de2-7EGFR, hereafter DEGFR), yet notably,
only a minority of tumor cells possess this lesion, while the remainder main-
tain expression of wild-type EGFR (wtEGFR). This disconnect between
tumorigenic potential and the frequencies and proportions of these receptors
might arise simply from a stochastic process wherein independent genetic
events arise in these rapidly fatal tumors, which never have the time to
become homogeneous. Another possibility is that DEGFR occurs later in
tumor progression, where the minority of cells that express it not only
enhance their own intrinsic tumorigenic abilities but also potentiate
through a paracrine mechanism the proliferation of neighboring majority
cells expressing amplified wtEGFR. To test these hypotheses, we engrafted
wtEGFR-expressing glioma cells into mice and examined the ability of
various amounts of co-injected DEGFR-expressing cells to influence tumori-
genic growth. We also examined conditioned media produced from
DEGFR-expressing cells (DEGFR-CM) for its ability to activate signaling
pathways in wtEGFR-expressing cells and for the presence of potential para-
crine factors. From these experiments we determined that human glioma
tissues, glioma cell lines, glioma stem cells, and primary mouse astrocytes
that express DEGFR each secrete IL-6 and/or LIF cytokines. This then
prompts a novel interaction between the receptor that is common to these
cytokines, gp130, and wtEGFR in neighboring cells that express amplified
levels of EGFR, resulting in co-receptor activation and tumor growth
enhancement mediated through the activation of gliomagenic signature mol-
ecules Akt, MAPK, and STAT3. siRNA knockdown of IL-6, LIF, or gp130
uncouples this cellular crosstalk and potently attenuates tumor growth
enhancement. These findings demonstrate that the heterogeneity that charac-
terizes GBM does not occur stochastically but instead can be an actively
maintained feature and illuminates a heterotypic cancer cell interaction of
potential therapeutic significance.
CB-36. ALTERED APKC SIGNALING CONTRIBUTES TO
GLIOBLASTOMA CELL MIGRATION
Yael Kusne 1, Ari Meerson 1, Elisabeth J. Rushing 2, Weiwei Yang 3,
Kenneth Aldape 3, Wendy McDonough 4, Kerri Kislin 4, Joseph C. Loftus 5,
Michael Berens 4, Zhimin Lu 3, and Sourav Ghosh 1; 1University of Arizona;
2AFIP; 3The University of Texas MD Anderson Cancer Center; 4TGen;
5Mayo Clinic Arizona
Asymmetry along an apical-basal axis or apical-basal polarity is essential
for a number of biological processes, including asymmetric segregation of
cell fate and differentiation, regulation of cell-cell adhesion, and vectorial
cell migration. These processes are fundamental for organogenesis and
embryonic development as well as for tumorigenesis and metastasis.
We have demonstrated that atypical protein kinase C (aPKC) provides an
instructive signal for apical-basal polarity in NSC during embryonic develop-
ment of the chick CNS. aPKC is compartmentalized at the apical membrane
of neural progenitors, and disrupting the endogenous localization of this
kinase results in a loss of apical cell adhesion junctions, increased prolifer-
ation of neural progenitors, and abnormal migration of these cells within dif-
ferentiated cell layers. Can aPKC and apical-basal signaling pathway be also
associated with abnormal cell proliferation and invasiveness of central
nervous system tumors such as glioblastoma (GBM) We have demonstrated
that aPKC staining is significantly enhanced in clinical samples of GBM.
aPKC functions downstream of the oncogenic EGFR-Ras-PI3-K cascade in
glioma cells. The knockdown of aPKC in GBM-derived cell lines decreases
cell migration. Our studies suggest that aPKC, a protein kinase and thus a
highly attractive target for rational drug design, may be a novel therapeutic
target in GBM.
CB-37. EGFR AS A PREDICTOR OF RELAPSE AND A POTENTIAL
THERAPEUTIC TARGET IN RECURRENT DISSEMINATED
MYXOPAPILLARY EPENDYMOMA
AnupamVerma 1, HollyZhou 2, StevenChin 3, CarolBruggers 1, JohnKestle 1,
and Soumen Khatua 1; 1Primary Children’s Medical Center; 2Primary
Children’s Medical Center, Department of Pathology; 3Department of
Anamotic Pathology, University of Utah
INTRODUCTION: Myxopapillary ependymomas (MEPN) are a rare
subtype of ependymoma in children, occurring most commonly in the lum-
bosacral region. Although these tumors are considered Grade I per the
World Health organization, having a tendency for slow growth and local
recurrence, they are capable of leptomeningeal dissemination. The rarity of
these tumors and the unpredictable behavior of relapse have made these
tumors a therapeutic challenge. To date, no defined molecular markers
have been established at the gene or protein level that could be predictive
of disseminated recurrence in MEPN. METHODS: We reviewed medical
records and identified seven patients with MEPN from 1995 to 2009. Of
these, four had recurrent tumors, and three did not have a recurrence. We
looked into protein expression of Mib-1, survivin, and EGFR using immuno-
histochemistry (IHC) to see whether they could be predictive of relapse.
RESULTS: EGFR expression was found to be a likely predictor of relapse.
IHC showed strong EGFR protein expression in four patients with recurrent
tumors, both at diagnosis and at recurrence. However, the three patients
without recurrence did not show any EGFR expression. Mib-1 and survivin
expression did not differ between tumors with and without recurrence.
CONCLUSION: This small case series demonstrates for the first time that
EGFR protein expression by IHC could be a potential biological marker of
recurrence and may play an important role in tumorigenesis in MEPN. A
large prospective study is warranted to determine whether EGFR protein
expression at diagnosis in MEPN is predictive of recurrence, which would
help in profiling an optimal follow-up pattern. This study also shows that
EGFR could be a potential therapeutic target in these tumors when they
relapse, as no standard therapy exists beyond surgery.
CB-38. REVERSAL OF EFFECT OF U87 DERIVED
MICRO-VESICLES ON BIOLOGICAL PROCESSES
OF GLIOBLASTOMA MULTIFORME
Marike L.Broekman 1, Niek S.Maas 2, JohanSkog 3, Xandra O.Breakefield 3,
and Miguel Sena-Esteves 4; 1University Medical Center; 2University Medical
Center Utrecht; 3Massachusetts General Hospital; 4University of
Massachusetts Medical School
BACKGROUND: Micro-vesicles, also known as exosomes, are extracellu-
lar, membrane-bound vesicles derived from the intralumenal membranes of
multivesicular bodies (MVBs) of the endocytic pathway. These MVBs fuse
with the plasma membrane, which causes the release of vesicles into the extra-
cellular environment. Various cell types, including tumor cells, have been
shown to produce micro-vesicles, which are believed to play a role in signal
transduction. Recently, glioblastoma-derived micro-vesicles have been
shown to contain proteins and RNA. Since micro-vesicles from different
tumor cells appear to be involved in different biological processes, we set
out to investigate the influence of U87 micro-vesicles on multiple biological
processes. METHODS: First, we isolated (for the first time) micro-vesicles
from U87 cells by step-wise centrifugation. Next, we assessed the influence
of these vesicles on proliferation, angiogenesis, and migration by WST-1
assay, endothelial cell tubule formation on matrigel, and invasion assays,
respectively. After this, U87 cells were treated with interferon beta, and
their micro-vesicles were isolated and used to assess differential effects on
those biological processes and changes in protein and RNA content.
RESULTS: Microvesicles derived from untreated but not from treated U87
Abstracts













cells stimulate growth, angiogenesis, and migration of glioblastoma cells. The
contents of micro-vesicles derived from treated and untreated U87 cells show
differences, which explain the observed effects. CONCLUSION: U87 micro-
vesicles influence the behavior of glioblastoma cells. This can be reversed by
treating the cells with interferon beta.
CB-39. STUDYING THE ROLE OF EXOSOMES IN
GLIOBLASTOMA TUMOR BIOLOGY
Jeroen de Vrij 1, Martine Lamfers 1, Niek Maas 2, Clemens Dirven 1,
Miguel Esteves 2, and Marike Broekman 3; 1Erasmus Medical Center;
2Department of Neurology, University of Massachusetts Medical School;
3Department of Neurosurgery and Rudolf Magnus Institute of
Neuroscience, University Medical Center Utrecht
The highly invasive nature of malignant brain tumors (gliomas) precludes
the complete surgical resection of these tumors and contributes to the poor
prognosis of glioma patients. Exosomes are excreted micro-vesicles,
50-90 nm, which form from the fusion of multivesicular bodies (MVB)
with the plasma membrane. A multitude of studies suggests a biological
role of exosomes in cell-to-cell communication, contributing, for example,
to antigen presentation to T cells. Evidence for a role of exosomes in
tumor biology has been obtained as well. Recent studies have shown that
tumor-derived exosomes carry mRNA, miRNA, and angiogenic proteins.
Glioblastoma tumor-derived exosomes can deliver their contents to other
cells and possibly be one of the pathways by which tumor cells manipulate
their microenvironment (e.g., GBM exosomes have angiogenic properties).
The main objective of our project is to investigate the effects of down-
modulating exosome production on the biology of brain tumors, including
through studies of angiogenesis, cell growth, and cell migration. One of
our strategies encompasses the down-regulation of different genes that
were previously shown to be involved in the exosomal release pathway. To
this end, we use viral vectors to deliver short hairpin RNA to the tumor cells.
CB-40. THE ROLE OF WILM’S TUMOR-1 (WT-1) IN GLIOMA
BIOLOGY
Archana Chidambaram , Catherine I. Dumur , Martin Graf , Timothy
E. Vanmeter , Helen L. Fillmore , and William C. Broaddus ; Virginia
Commonwealth University
INTRODUCTION: The zinc-finger transcription factor, WT-1, is known
to play a vital role in the development of several organ systems and is down-
regulated in most adult tissues. However, WT-1 has also been found to be
re-expressed in malignancies arising from different tissue types. Our lab
has previously demonstrated that this protein is aberrantly expressed in
glioma cells and plays an important role in tumor cell proliferation in vitro
and in vivo and in conferring radio- and chemo-resistance to the tumor
cells. This study aimed to determine whether the tumor cells expressing
WT-1 belong to the CD-133 positive subpopulation and to elucidate the
mechanisms by which the tumorigenic actions of this protein may be
wrought. METHODS AND RESULTS: We used flow cytometry to deter-
mine whether WT-1 and CD-133 are co-expressed by the same cell subpopu-
lation. The gene expression profiling technique was used to identify the target
genes for WT-1 in U251-MG cells. Preliminary results suggest that WT-1
might regulate genes involved in different aspects of tumorigenesis especially
cell proliferation (PDGF-A, ICK), angiogenesis (CD97, EPAS-1), invasive-
ness (PDGF-D), and different phases of the cell cycle (TYMS, LZTS-1).
Using real-time RT-PCR, we validated these findings and noted similar regu-
lation of some of these genes in U1242-MG cells. Transient knockdown of
WT-1 in these cells resulted in an alteration of the malignant phenotype of
the U1242-MG cells. CONCLUSION: Our results clearly implicate WT-1
as a key player in glioma pathogenesis. Future studies shall seek to delineate
the role(s) of the target genes established herein so as to provide important
insights for the development of a multi-molecular targeting strategy
against these aggressive tumors.
CB-41. AN ANALYSIS OF THE ROLE OF MICRORNAS IN THE
PHENOTYPIC EXPRESSION OF ONCOGENIC PDGF SIGNALING
IN MALIGNANT GLIOMA
Joachim Silber , Tatsuya Ozawa , Edward Kastenhuber , Hakim Djaballah ,
Eric C. Holland , and Jason T. Huse ; Memorial Sloan-Kettering Cancer
Center
Malignant gliomas continue to cause a disproportionate degree of morbid-
ity and mortality among cancer patients while demonstrating sobering
resistance to conventional therapies. Recent comprehensive genomic ana-
lyses have emphasized the importance of receptor tyrosine kinases (RTKs)
and their downstream signaling cascades in the process of gliomagenesis.
Among these, the platelet-derived growth factor (PDGF) pathway appears
to play a crucial role in the initiation and maintenance of both low- and high-
grade diffuse gliomas. An improved understanding of how PDGF signaling
mediates its oncogenic effects and the mechanisms for its regulation would
be of obvious benefit to the development of effective targeted therapeutics.
MicroRNAs (miRNAs) are a class of small, noncoding RNAs that regulate
gene expression on a pre-translational level by binding loosely complimen-
tary sequences in target mRNAs. Each miRNA likely represses numerous
mRNA targets, and this promiscuity speaks to the ability of individual
miRNAs to mediate complex biological phenotypes. We have recently
begun an analysis of miRNA involvement in the phenotypic expression
and regulation of oncogenic PDGF signaling. We have identified a group
of miRNAs whose expression levels are responsive to PDGF pathway acti-
vation in vitro and have recapitulated these findings in human glioblastomas,
particularly those driven by aberrant PDGF signaling. We are now evaluating
the functional properties of these miRNAs in a variety of in vitro and in vivo
systems and investigating the mRNA targeting profiles of each using a com-
bination of expression arrays and bioinformatics. We are also performing
high-throughput screens to identify miRNAs that directly repress PDGF sig-
naling and its downstream pathways. Through our studies, we hope to ident-
ify miRNA-based regulatory events impacting PDGF-mediated oncogenesis
that may be amenable to therapeutic intervention.
CB-42. DEVELOPMENTAL PROFILE AND REGULATION OF
THE GLYCOLYTIC ENZYME HEXOKINASE 2 IN NORMAL
BRAIN AND GLIOBLASTOMA MULTIFORME
Amparo Wolf , Sameer Agnihotri , Diana Munoz , Cynthia Hawkins , and
Abbhijit Guha ; University of Toronto
INTRODUCTION: Proliferating embryonic and tumor cells switch to
aerobic glycolysis, whereby glucose is metabolized to lactate rather than
undergoing oxidative phosphorylation (OXPHOS), even in the presence of
oxygen. This metabolic switch provides a survival advantage and facilitates
the synthesis of biosynthetic precursors required for continued cellular pro-
liferation. An example of this switch is our demonstration that in malignant
gliomas there is over-expression of the glycolytic enzyme Hexokinase 2
(HK2) resulting in enhanced aerobic glycolysis. In contrast, normal brain
preferentially expresses HK1 and undergoes OXPHOS. In this study, we
examined whether this switch in HK isoform also occurs in the developing
embryo and central nervous system (CNS). METHODS/RESULTS:
Bioinformatic analysis of available microarray data demonstrated higher
expression of glycolytic genes including HK2, but not HK1, in the blastocyst
stage, previously reported to favor aerobic glycolysis, compared to the 1-, 2-,
4-, 8-cell stages. Quantitative RT-PCR on mouse brains isolated at E8.0,
E10.5, E15.5, postnatal day 1, day 20, and 2 months, demonstrated that
HK2 expression was highest at early embryonic developmental time-points,
while HK1 expression increased with CNS maturation and relative quies-
cence. LDHA expression profile mimicked that of HK2. This temporal regu-
lation of HK2 was secondary to epigenetic methylation of the HK2
promoter. Adult normal human brain and the few human GBM cell lines
with decreased HK2 expression showed greater methylation of CpG
islands within intron 1 of the HK2 promoter. In contrast, the HK2 promoter
of the developing human fetal brain and the vast majority of HK2-expressing
human GBM cell lines were not methylated. Furthermore, 5-azacytidine
treatment of GBM cells lacking HK2 restored HK2 transcript expression.
CONCLUSIONS: Overall, our results demonstrate that switch to the HK2
isoform is associated with proliferating states, such as the developing brain
in embryos or as in malignant gliomas.
CB-43. STAT3 INHIBITION ALTERS THE IMMUNE PROFILE IN
MURINE GLIOMAS
James E. Han , Emilia Albesiano , GustavoPradilla , and MichaelLim ; Johns
Hopkins University School of Medicine
Signal transducer and activator of transcription 3 (STAT3) has shown to
be constitutively activated in a broad array of human and murine tumors.
The role of STAT3 in cellular proliferation, angiogenesis, apoptosis, and
migration has been well documented. However, STAT3 activation also
induces a procarcinogenic anti-inflammatory microenvironment that
antagonizes innate and adaptive antitumor immune responses. We first
detected in vitro STAT3 activation on murine glioma cell lines (GL261
and GL26) and in vivo STAT3 activation on paraffin-embedded sections of
basal ganglia regions of C57/BL6 mice implanted with those cell lines. We
then electroporated GL261 and GL26 to transiently transfect with siRNA
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anti-STAT3, resulting in substantial down-regulation of STAT3 by
80%–90% in both cell lines at the mRNA and protein level. In addition,
we analyzed the effects of STAT3 suppression by measuring transcription
of mRNA for selected cytokines (IFN-beta, IL-6, IL-10) and chemokines
(RANTES, IP-10) using qRT-PCR. STAT3 inhibition in murine glioma cell
lines resulted in enhanced expression of both pro-inflammatory cytokines
and chemokines as compared to untreated controls. We found increased
levels of IFN-gamma-inducible protein 10 (IP10) and IFN-beta, decreased
levels of IL-6, constant levels of RANTES, and varying levels of IL-10 in
both cell lines. These findings are similar to those in murine melanoma
(B16) and colon carcinoma (CT26) models. However, subtle differences do
exist, revealing that different types of cancers may respond in a unique
manner. These results demonstrate the important role that STAT3 activation
plays in suppressing the release of inflammatory chemokines and cytokines in
a murine glioma model. STAT3 inhibition is a potential target for glioma
therapy, as multiple upstream cytoplasmic signaling pathways converge
upon it. Future in vivo studies will be conducted to determine whether
STAT3 inhibition can reverse tumor-promoting inflammation and generate
a potent antitumor response.
CB-44. A CONTINUUM OF MGMT PROMOTER
METHYLATION AND MGMT ACTIVITY
Jad Alshami , Carmen Sabau , Mohamad Seyed Sadr , Mitsuhiro Anan ,
Emad Seyed Sadr , Vince Siu , and Rolando Del Maestro ; Brain Tumour
Research Centre, Montreal Neurological Institute, McGill University
INTRODUCTION: Epigenetic methylation of the MGMT promoter in
glioblastoma is associated with improved survival in patients treated with
concomitant temozolomide and radiotherapy followed by adjuvant temozo-
lomide. The current assessment of the MGMT promoter methylation status
is binary. Malignant brain tumors are very heterogeneous. We hypothesize
that the existence of a continuum of MGMT promoter methylation in the
tumor rather than a binary function would provide a more accurate assess-
ment of MGMT expression and activity. METHODS: To assess this hypoth-
esis, quantitative in vitro cell mixing experiments were carried out using U87
(methylated MGMT promoter) and Daoy (unmethylated MGMT promoter)
cell lines. Pyrosequencing and methylation-specific PCR (MSP) evaluated
MGMT promoter methylation status both as a binary function and as a
methylation percentage value. MGMT RNA expression, MGMT protein
expression, and MGMT activity were also evaluated in each mixed popu-
lation. Excised normal gray and white matter and brain tumor tissues
(methylated and unmethylated MGMT promoter) were mixed and similar
assessments carried out. RESULTS: MGMT activity was associated with
protein expression and mRNA levels in the in vitro mixing experiments.
MGMT promoter methylation was proportional to MGMT activity only
when assessed as a methylation percentage value rather than a binary func-
tion. In the brain tumor mixing experiments, similar results were observed,
suggesting the evaluation of the MGMT promoter methylation status calcu-
lated as a methylation percentage value appears to give a more accurate
assessment of MGMT expression and activity in these studies.
CONCLUSION: The evaluation of the MGMT promoter methylation as a
percentage value rather than a binary function resulted in an accurate predic-
tion of MGMT expression and activity assessed in these in vitro studies.
CB-45. DRR – POTENTIAL REGULATOR OF GLIOMA INVASION
GinaTrinh , PhuongLe , and KevinPetrecca ; Montreal Neurological Institute
Malignant gliomas are highly invasive and thereby evade complete surgi-
cal resection. Using a novel screening assay, we have uncovered a potential
regulator of invasion: down-regulated in renal cell carcinoma (DRR). DRR
is expressed in all invasive components of brain tumors but not in normal
brain glia. DRR overexpression causes increased migration compared to
control malignant glioma cells (MGCs). Conversely, knocking down DRR
in MGCs abolishes invasion. The process of cellular invasion requires remo-
deling of the cytoskeleton, particularly proteins involved in actin stress fibres
and focal adhesion formation. The small family of Rho GTPases (Rho, Rac,
and Cdc42) is the primary regulator of cytoskeletal dynamics. DRR
expression induces morphological changes, such as cell elongation and
robust actin stress fibers—a typical Rho phenotype. Complimentarily, our
down-regulated DRR cells show virtually no stress fibers, with a peripheral
distribution of focal adhesions—a typical Rac phenotype. Therefore, we
propose that DRR may facilitate cell invasion by altering the dynamics of
Rho/Rac signaling. In addition to MGCs, glioblastoma primary cultures
will also be used to test DRR as potential target for therapy. We hope to elu-
cidate the mechanisms by which DRR mediates cell invasion and thus expose
a possible strategy to inhibit glioma invasion.
CB-46. EVOLUTION OF GLIOBLASTOMA IS DETERMINED BY
THE INITIATING GENETIC HITS
Adam M. Sonabend 1, Craig Soderquist 2, Liang Lei 2, Paolo Guarnieri 3,
RichardLeung 2, JonathanYun 2, Julia Sisti 2, MikeCastelli 2, Samuel Bruce 2,
Rachel Bruce 2, Thomas Ludwig 4, Steven Rosenfeld 5, Jeffrey N. Bruce 2, and
Peter Canoll 6; 1Gabriele Bartoli Brain Tumor Laboratory, Irving Research
Cancer Center, Department of Neurosurgery, Columbia University;
2Gabriele Bartoli Brain Tumor Laboratory, Irving Research Cancer Center,
Department of Neurosurgery, Columbia University, New York, NY, United
States; 3Bioinformatics Department, Irving Research Cancer Center,
Columbia University, New York, NY, United States; 4Irving Research
Cancer Center, Columbia University, New York, NY, United States;
5Gabriele Bartoli Brain Tumor Laboratory, Irving Research Cancer Center,
Columbia University, New York, NY, United States; 6Gabriele Bartoli Brain
Tumor Laboratory, Irving Research Cancer Center, Departments of
Pathology and Neurosurgery, Columbia University, New York, NY, United
States
INTRODUCTION: The genetic diversity of glioblastoma (GBM) consti-
tutes a major obstacle to effective therapies. We hypothesize that defining
the relationship between the initiating genetic hits and end-stage genotype
will provide a means to understand and predict tumor evolution.
METHODS: Mouse gliomas were induced by injecting PDGF-IRES-Cre
retrovirus (RV) into transgenic mice with floxed PTEN and p53 genes
and from cells isolated from these tumors (*PTEN/p53 and *PTEN).
DNA from RV-induced tumors (n ¼ 24) was analyzed by comparative
genomic hybridization (CGH) and sequencing. Results were compared to
the genotype of human GBM from the TCGA database. RESULTS: For
the RV-induced tumors, *PTEN/p53 had a significantly shorter survival
than *PTEN tumors; however, transplantation of cells from end-stage
*PTEN and *PTEN/p53 led to a similar survival, suggesting that
*PTEN evolved to become as aggressive as *PTEN/p53 tumors.
Numerous genetic deletions were consistently seen in the *PTEN gliomas
(75%–100%) but were rarely seen in *PTEN/p53 tumors (0%–12.5%),
suggesting that deletion of p53 obviated the selective advantage of these
additional deletions. Furthermore, 40% of *PTEN developed non-silent
mutations within hotspots on the DNA-binding domain of p53.
Comparison with TCGA data revealed that the genetic alterations seen in
*PTEN gliomas (.75%) recapitulate those seen in the pro-neural
subtype of human GBM. Moreover, deletion of some of these genes is
associated with short patient survival. CONCLUSIONS: These results
demonstrate that the evolution of GBM is remarkably predictable and
dependent on the initiating genetic hits. Tumor evolution in this model
resembles that of the pro-neural subtype of human GBM. Both cases are
characterized by PDGF signaling, p53 mutations, and a specific set of
common genetic deletions that we identified by CGH. Mouse-to-human
comparisons revealed that these deletions are clinically relevant. These find-
ings constitute an important step toward predicting the evolution of GBM
and developing personalized-based therapies.
CB-47. SULF2, A HEPARAN SULFATE SULFATASE, REGULATES
CRITICAL CELL SIGNALING PATHWAYS IN GLIOBLASTOMA
GROWTH
Joanna J. Phillips , Emmanuelle Huillard , Mei-Yin Polley , Steven D. Rosen ,
David H. Rowitch , and Zena Werb ; UCSF
Glioblastoma (GBM) is characterized by abnormal activation of receptor
tyrosine kinase (RTK) signaling pathways. As GBMs diffusely invade,
growth factor availability in the tumor microenvironment could be a critical
determinant of RTK signaling pathway activity. Heparan sulfate proteogly-
cans (HSPGs), a major component of the brain extracellular matrix, regu-
late the extracellular activity of diverse growth factors. As the sulfation
pattern of the HS chains is a major determinant of this activity, we hypoth-
esize that GBMs enzymatically modify HSPGs to promote growth factor
signaling. We demonstrate that the extracellular sulfatase SULF2, which
acts on HSPGs, is expressed in 50% of primary human GBM and in an
orthotopic murine model for high-grade glioma. Knockdown of SULF2 in
GBM cells resulted in decreased growth in vitro and in vivo, and revealed
a striking SULF2 dependence in the activity of multiple RTKs, including
PDGFR-alpha, a major signaling pathway in glioma. Furthermore,
tumors generated from Sulf22/2 neural progenitor cells were smaller
with decreased proliferation, were associated with prolonged survival,
and had decreased PDGFR-alpha phosphorylation and decreased down-
stream MAPK signaling pathway activity. Interestingly, we show that
GBM subtypes demonstrate dramatically different SULF2 expression.
These data support a key role for SULF2 in an important subset of GBM
and identify a potential upstream therapeutic target regulating RTK signal-
ing in GBM.
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CB-48. HEDGEHOG-GLI SIGNALING PATHWAY IN GLIOMAS:
CORRELATION WITH HISTOLOGY, GENETIC ALTERATIONS,
AND EXPRESSION OF STEMNESS MARKERS
ChitraSarkar , PreranaJha , PankajPathak , VaishaliSuri , Mehar C.Sharma ,
Parthoprasad Chattopadhyay , Kunzang Chosdol , Ashish Suri ,
Deepak Gupta , and Ashok K. Mahapatra ; All India Institute of Medical
Sciences
Brain tumors can arise following deregulation of signaling pathways nor-
mally activated during brain development. Sonic hedgehog-Gli1 (SHH-Gli1)
is one such important pathway whose role has been well established in
medulloblastomas; however, the few reports in gliomas have yielded conflict-
ing results. Further, since the SHH-Gli1 pathway plays a critical role in non-
neoplastic stem cells, its role in stem-like neoplastic cells needs further evalu-
ation. Hence, in this study, we evaluated 102 gliomas for SHH-Gli pathway
activity and correlated with histological type and grade, genetic alterations,
and expression of stemness markers NANOG, OCT4, SOX2. The study was
performed on 44 grade IV (GBM), 23 grade III (10 AA, 9 AO, 4 AOA), and
35 grade II (20 DA, 9 O, 6 OA) tumors. World Health Organization classi-
fication was done and genetic subsets defined based on TP53 mutation,
EGFR amplification, and 1p/19q LOH. Real-time polymerase chain reaction
was performed for expression of Gli1, SHH, PTCH, NANOG, OCT4, and
SOX2. Western blot was done for SHH and Gli1 protein expression.
There was inverse correlation of high Gli expression (.1.5) with histological
grade (51% grade II, 22% grade III, and 16% grade IV). Two-thirds of
GBMs with high Gli showed EGFR amplification versus 25% with low
Gli. High Gli1 was associated with expression of SHH and PTCH in 97%
and 81% cases, respectively. A significant correlation of high Gli1 with stem-
ness markers was also noted. Thus, 93% of gliomas with high Gli1 had
expression of stemness markers versus 38% with low Gli. This study con-
firms the presence of an active ligand-driven SHH-Gli pathway in a subset
of gliomas of all types with inverse correlation to grade. The positive corre-
lation of Gli1 with stemness markers possibly indicates that more differen-
tiated progeny of tumor cells may be reverting to a “stem-like status” by
activation of this pathway.
CB-49. MOLECULAR INTERACTION BETWEEN PTEN AND
EGFRVIII/SHP-2 ACTIVATION COMPLEX AFFECTS
GLIOBLASTOMA SENSITIVITY TO TYROSINE KINASE
INHIBITORS (TKIS)
Gurpreet S. Kapoor 1, Yi Zhan 1, John A. Boockvar 2, and Donald
M.O’Rourke 1; 1University of Pennsylvania; 2Weill Cornell Medical College,
Cornell University
Co-expression of EGFRvIII and PTEN in a small subset of recurrent glio-
blastoma tumors has been shown to increase sensitivity to tyrosine kinase
inhibitors (TKIs). However, the exact mechanism of EGFRvIII and PTEN
interaction in response to TKIs is still unresolved. Our recent work has
shown that SHP-2 PTPase is required for EGFRvIII-mediated transform-
ation. The present work was aimed at investigating the molecular interaction
between the EGFRvIII/SHP-2 activation complex and PTEN in response to
Tarceva treatment. We show that Tarceva treatment abolished EGFRvIII,
EGFR, Gab1, SHP-2, and Erk1/2 phosphorylation in LN229.EGFRvIII
cells at all time intervals. On the contrary, phosphorylation of EGFRvIII
and Erk1/2 in U87MG.EGFRvIII cells was inhibited at early time points
but was restored within 2 to 6 hours. Interestingly, phosphorylation of
Akt, Gab1, and SHP-2 (Tyr580) was unaffected in U87MG.EGFRvIII
cells, but EGFR and SHP-2 (Tyr542) phosphorylation was inhibited in a
time-dependent manner. MTT proliferation and soft agar transformation
assays demonstrated that U87MG.EGFRvIII cells were resistant to Tarceva
treatment when compared to LN229.EGFRvIII cells. Immunofluorescent
labeling of U87MG.EGFRvIII cells with an antiphospho-SHP-2 (Tyr542)
antibody showed perinuclear localization of SHP-2, whereas
LN229.EGFRvIII cells exhibited membrane staining of phosphorylated
SHP-2. Interestingly, stable expression of PTEN in U87MG.EGFRvIII cells
conferred relocalization of phospho-SHP-2 (Tyr542) to the membrane.
Notably, U87MG.EGFRvIII/PTEN clones showed a partially untrans-
formed phenotype. Furthermore, phosphorylation of SHP-2 (Tyr580) and
Erk1/2 was totally abolished in U87MG.EGFRvIII/PTEN subclones. Our
data indicate that the expression of PTEN in U87MG.EGFRvIII cells con-
ferred a phenotype similar to LN229.EGFRvIII cells. Collectively, these
observations allow us to infer that SHP-2 is a downstream effector of
PTEN and that PTEN deficiency may lead to SHP-2 activation and peri-
nuclear localization by EGFRvIII, which may result in increased resistance
to TKIs. Future studies will be aimed at further understanding the role of
SHP-2 activation and translocation in glioblastoma response to TKI
treatment.
CB-50. DIFFERENTIAL EXPRESSION OF FULL-LENGTH AND
TRUNCATED NEUROKININ 1 RECEPTORS IN GLIOBLASTOMA
CELLS
Madan M. Kwatra ; Duke University Medical Center
Neurokinin 1 receptor (NK1R) is a G protein-coupled receptor that
mediates the effects of neuropeptide substance P. In 1995, NK1R was impli-
cated in glioblastomas (GBM) when Henning et al. (1) showed that NK1R
is expressed in 9 of 12 astrocytomas and 10 of 10 GBM and that the
expression of NK1R correlates with degree of malignancy, with GBM
expressing more receptors than grade I-III astrocytomas. At the molecular
level, NK1R stimulation in U373 MG human GBM cells increases mitogen-
esis and cell proliferation, release of interleukin-6, activation of NF-kappaB,
and transactivation of epidermal growth factor receptor (EGFR). A recent
study from our laboratory further implicates NK1R by demonstrating
that NK1R stimulation leads to an increase in phosphorylation and activity
of Akt (2). Our study also demonstrated the presence of a constitutively
active form of NK1R in GBM cells (2). We now show that the constitutively
active form of NK1R arises from the truncated variant of NK1R. Further,
we show that the expression of the truncated form of NK1R varies in differ-
ent GBM cells. The truncated form differs from full-length NK1R in that it
lacks a carboxyl tail. Apparently, the truncated NK1R is an oncogene: a
study published in 2005 demonstrated that the expression of truncated
NK1R but not full-length NK1R in normal breast cells resulted in a trans-
formed phenotype (3). Taken together, these studies suggest that targeting
NK1R either alone or in combination with targets such as EGFR and
IGFR-1 is a potentially useful strategy for inhibiting the growth of GBM.
References: 1. Hennig et al., Int J Cancer, 1995; 61: 786–92. 2. Akazawa
et al., J. Neurochem. 2009; 109: 1079–86. 3. Patel et al., Proc Natl Acad
Sci U S A, 2005; 102:17436–41.
CB-51. THE USEFULNESS OF MS-MLPA FOR DETECTION OF
MGMT PROMOTER METHYLATION IN THE EVALUATION OF
PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
Jin Wook Kim 1, Chul-Kee Park 1, Jung Ho Han 2, Sung Hye Park 1,
Seung-Ki Kim 1, and Hee-Won Jung 1; 1Seoul National University Hospital;
2Seoul National University Bundang Hospital
Pseudoprogression is a major diagnostic dilemma in the current treatment
protocols for malignant gliomas that involve concurrent chemoradiotherapy.
We hypothesized that methylation-specific multiplex ligation probe amplifi-
cation (MS-MLPA), an assay that permits semiquantitative evaluation of
promoter methylation, may be used to diagnose pseudoprogression based
on the quantification of the methylation status of the O6-methylguanine
DNA methyltransferase (MGMT) promoter. We examined the methylation
ratio and copy number variation of the MGMT promoter and mismatch
repair (MMR) genes with MS-MLPA in 24 samples from glioblastoma
patients. The results were compared to those from methylation-specific poly-
merase chain reaction (MSP), and protein levels were confirmed by immuno-
histochemical (IHC) staining. We then evaluated the correlation between
those molecular signatures and clinical outcomes. With regard to radiologi-
cal progression after chemoradiotherapy, the sensitivity and specificity of the
MS-MLPA were 100% and 75%, respectively. These results are better than
those obtained with MSP (using cut-off values of 0.2 for the methylation
ratio and 0.8 for the copy number ratio) for the identification of pseudopro-
gression. The results of MS-MLPA evaluation of MGMT methylation corre-
lated well with those from MSP and IHC staining, but there was no
significant correlation between MSP and IHC staining. MMR genes had
little variability in promoter methylation, and their protein products demon-
strated homogeneous tissue expression. We conclude that MS-MLPA is a
useful method for the early detection of pseudoprogression in glioblastoma
patients.
CB-52. A COMBINATORIAL ZINC-FINGER LIBRARY
APPROACH TO EXPLORING TEMOZOLOMIDE RESISTANCE
IN GLIOBLASTOMA
Radhakrishnan Narayanan 1, Benjamin S. Levin 2, Morgan L. Maeder 2,
J K. Joung 2, Catherine L. Nutt 2, and David N. Louis 2; 1Massachusetts
General Hospital, Harvard Medical School; 2Massachusetts General
Hospital, Harvard Medical School, Boston
Recent therapeutic advances have improved control of glioblastomas, with
a significant fraction of tumors responding to initial therapies.
Unfortunately, all glioblastomas recur and lead to patient death. In an
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effort to better understand therapeutic resistance, we have explored high-
dimensional profiling studies to understand mechanisms of therapeutic
resistance and to identify novel therapeutic targets. Temozolomide (TMZ)
is an alkylating chemotherapeutic agent that is used to treat all glioblasto-
mas. Recurrent glioblastomas, however, become resistant to TMZ through
a mechanism associated with inactivation of MSH6, a member of the mis-
match repair gene family; MSH6-deficient glioblastomas grow more
rapidly during TMZ therapy. To explore pathways of therapeutic resistance,
we have designed an unbiased drug resistance selection screen to create
TMZ-resistant human glioblastoma cell lines using combinatorial zinc-finger
transcription factors (ZTFs). The combinatorial ZTF library enables acti-
vation of a gene or a set of genes that will be selected for resistance to
TMZ. We have isolated resistant clones in the TMZ-sensitive A172 cell
line and present a molecular profile analysis of these clones. By comparative
gene expression profile analysis of novel ZTF-induced, TMZ-resistant glio-
blastoma cell lines, we expect to identify molecular pathways that confer
TMZ resistance. In doing so, we also aim to identify possible biomarkers
for TMZ resistance in recurrent glioblastomas.
CB-53. DRR PROMOTES CELL INVASION BY REGULATION OF
EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION
Alix Dudley ; McGill University
Glial cell invasion is a defining feature of malignant gliomas and is the
leading cause of treatment failure, yet the molecular mechanisms that regu-
late invasion are poorly understood. Using a functional genetic screening
assay, we identified down-regulated in renal cell carcinoma (DRR) as a
novel regulator of cell invasion. DRR is up-regulated in the invasive com-
ponent of all gliomas and is not expressed in normal glial tissue. The epider-
mal growth factor receptor (EGFR) is over-expressed in high-grade gliomas
and is well established as promoting glial cell invasion. Our aim was to inves-
tigate whether a link exists between DRR and EGFR to promote cell inva-
sion. Therefore, we assessed EGFR expression and downstream signaling
upon DRR expression. DRR up-regulation led to elevated EGFR mRNA
and protein expression. There was concurrent increased phospho-EGFR
and phospho-Akt with DRR over-expression. Our data suggests a relation-
ship between DRR and EGFR, but the specifics of this relationship remain
undetermined. Nevertheless, this may underlie a novel mechanism by
which tumor cells invade the surrounding brain. Further studies to investi-
gate the role of DDR in the EGFR pathway might provide therapeutic
options to suppress GBM invasion.
CB-54. BENEFICIAL GROWTH EFFECTS OF ACYL-COA
SYNTHETASE VL3 KNOCKDOWN IN HUMAN GLIOBLASTOMA
CELLS ARE NOT MEDIATED BY INCREASED AUTOPHAGY OR
APOPTOSIS
Prathap Jayaram 1,2,3, Zhengtong Pei 1,2, Xiahai Shi 1,2, John Laterra 1,2, and
Paul A. Watkins 1,2; 1Department of Neurology, Johns Hopkins University
School of Medicine; 2Hugo W. Moser Research Institute at Kennedy Krieger;
3American University of Antigua College of Medicine
Glioblastoma multiforme (GBM) is the most common primary malignant
brain tumor and is associated with a poor prognosis. Lipids are essential for
tumor membrane synthesis and are also key oncogenic signaling molecules.
Acyl-CoA Synthetase VL3 (ACSVL3), which activates long-chain fatty
acids and promotes lipid synthesis, is highly expressed in GBM tumors and
cell lines but is not detectable in normal glia. We previously reported that
ACSVL3 plays a crucial role in supporting U87 GBM cell proliferation and
tumorigenesis; ACSVL3 knockdown in U87 cells decreased anchorage-
dependent and -independent growth in culture, mitochondrial activity,
DNA synthesis, and growth of both subcutaneous and intracranial xeno-
grafts. We also showed that these beneficial effects of ACSVL3 knockdown
are mediated, in part, by disruption of Akt signaling pathways. We therefore
asked whether the effects of ACSVL3 knockdown on glioblastoma cell
growth were mediated by promotion of either apoptosis or autophagy.
Using several criteria (annexin-V labeling; caspase activation), we found
no evidence of increased apoptosis in ACSVL3-deficient U87 cells.
Similarly, several indicies of autophagy (acridine orange staining;
LC3-GFP expression) failed to show increased autophagy in U87 knock-
down cells. Based on these observations, we propose that the beneficial
effects of ACSVL3 depletion on U87 cells and xenograft proliferation have
as their basis alterations in cellular metabolism and/or signaling pathways.
(Supported by NIH grant NS062043.)
CB-55. BIOLOGICAL BASIS FOR MULTITARGETED THERAPY
IN MENINGIOMA PATIENTS
Christian Mawrin ; University of Magdeburg
Meningiomas are frequent intracranial or intraspinal tumors that result in
significant morbidity and/or mortality owing to tumor recurrence, critical
tumor locations, or malignant growth, as seen in atypical and anaplastic
meningiomas. Besides neurosurgery and radiotherapy, treatment options
are limited. We have started to explore the value of substances covered
under the group of multitargeted therapies for the treatment of human
meningiomas. By analyzing human tissue samples as well as various menin-
gioma cell culture models, we found that meninigiomas are characterized by
a clear activation of the mTOR signaling pathway. This pathway could be
effectively antagonized by specific mTOR inhibitors, which are already
used in clinical oncology. Another target was identified using inhibitors tar-
geting platelet-derived growth factor (PDGF) receptors. Here we not only
found a clear antiproliferative effect of specific substances inhibiting this
important signaling pathway but also delineated that FLT-3, a receptor tyro-
sine kinase not described in human brain tumors so far, could be down-
regulated in meningioma cells. Additionally, we could see a clear antimigra-
tory aspect, which is especially important for the treatment of invasive
meningiomas. Finally, by using a specific alpha-v-beta-3 inhibitor, we
could show that without cytotoxic or antiproliferative effects, this substance
had a clear antimigratory effect. Taken together, our data show that different
new chemotherapy options might be of value for the treatment of aggressive
meningiomas.
CB-56. DELETION OF THE SPARC ACIDIC DOMAIN OR
EGF-LIKE MODULE REDUCES SPARC-INDUCED MIGRATION
IN GLIOMA CELLS
Sandra A. Rempel and Heather M. McClung ; Henry Ford Hospital/Wayne
State University
Secreted protein acidic and rich in cysteine (SPARC) is up-regulated in all
astrocytoma grades. We showed that SPARC increases glioma invasion while
suppressing tumor growth. It is thought that different domains within the
protein may regulate these functions, suggesting domain-specific targeting to
inhibit invasion. The present goal was to determine whether the N-terminal
acidic domain or the EGF-like module within the follistatin-like domain are
involved in SPARC-induced migration through the previously reported p38/
HSP27 signaling pathway. Deletion constructs were created using site-directed
mutagenesis of a SPARC-green fluorescent protein (GFP) plasmid. Stable U87-
transfected clones expressing equal levels of GFP, wild-type SPARC-GFP, or
either of the mutants were selected. Intracellular localization was determined
by fluorescence imaging. Levels of construct expression and secretion and sig-
naling events were characterized by Western blot analyses. Migration was
examined on fibronectin using a wound assay and without matrix by
Transwell assay. The results demonstrate that unlike control GFP, wild-type
SPARC and mutant clones are perinuclear and are secreted. Migration was sig-
nificantly increased in wild-type SPARC-GFP-expressing cells over control
GFP-expressing cells (p , 0.001) in both migration assays. Deletion of either
the acidic domain or the EGF-like module significantly reduced migration
versus wild-type SPARC-GFP cells (p ≤ 0.033) in both assays. However, in
the wound assay, the deletion mutants migrated significantly more than GFP
control cells (p , 0.001). Western blot analysis showed that SPARC increased
expression and phosphorylation of HSP27 and increased p38 activation over
control cells. The acidic domain deletion mutant had an intermediate level of
HSP27 expression and phosphorylation; however, deletion of the EGF-like
module caused a dramatic decrease in HSP27 expression and phosphorylation.
In conclusion, both regions of interest regulated migration though p38/HSP27
signaling. Importantly, their impact on migration was influenced by the micro-
environment, and selective inhibition of SPARC-mediated migration/invasion
would likely require multi-domain targeting.
CB-58. THE JAK2 INHIBITOR AZD1480 EFFECTIVELY BLOCKS
JAK2/STAT-3 SIGNALING IN GLIOBLASTOMA TUMOR CELLS
AND HUMAN XENOGRAFT GLIOBLASTOMA TUMORS
Braden C. McFarland 1, Susan E. Nozell 1, Dennis Huszar 2, and Etty
N.Benveniste 1; 1University of Alabama at Birmingham; 2Cancer Bioscience,
AstraZeneca R&D Boston
The JAK/STAT pathway is an important signaling pathway that has been
implicated in glioma progression. We have previously shown that STAT-3 is
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elevated and persistently activated in human glioma samples compared to
control tissues. In addition, this correlates with elevated levels of many
STAT-3 target genes, which promote tumor progression. To develop a thera-
peutic strategy to inhibit STAT-3 signaling, we have evaluated the effects of
AZD1480, a pharmacological inhibitor of JAK2. It has previously been
shown that AZD1480 effectively inhibits the growth of multiple tumor
types, but the effect on glioblastoma tumors has not been reported. In this
study, the efficacy of AZD1480 was tested in two human glioma cell lines,
U251-MG and U87-MG, as well as a mouse glioma cell line, 4C8.
AZD1480 effectively blocks constitutive and stimulus-induced JAK2 and
STAT-3 phosphorylation in both human and mouse glioma cells.
AZD1480 also decreases cell viability of U251-MG and U87-MG cells as
measured by the MTT assay. Furthermore, we used human xenograft
samples as models for the study of STAT-3 signaling in vivo. Unlike
human glioma cell lines passaged in vitro, human glioma samples that
have been propagated as xenografts in nude mice retain both the hallmark
genetic alterations and the invasive phenotype seen in vivo. In these
tumors, we show that STAT-3 is constitutively phosphorylated, but the
levels vary among tumors, which is consistent with human tumor samples.
We found that AZD1480 inhibits the phosphorylation of STAT-3 in these
xenograft tumor samples. However, more studies need to be done to validate
these results and demonstrate the potential inhibition of tumor growth in
vivo. Our results suggest that pharmacological inhibition of the JAK2/
STAT-3 pathway by AZD1480 reveals the potential for therapeutic inhi-
bition in malignant gliomas.
CB-59. THE PRO-CELL DEATH BCL-2 FAMILY MEMBER BNIP3
PROMOTES TUMOR CELL SURVIVAL IN GLIOBLASTOMA
MULTIFORME (GBM) THROUGH THE TRAIL/DEATH
RECEPTOR PATHWAY
Teralee Burton , David D. Eisenstat , and Spencer B. Gibson ; University of
Manitoba
BNIP3 is a hypoxia-inducible pro-cell death member of the Bcl-2 family.
BNIP3 is activated by the transcription factor HIF-1-alpha and mediates
cell death in a caspase-independent manner. Glioblastoma (GBM) is resistant
to most treatments. Response to therapy fails, in part, due to tumor hypoxia
facilitating resistance to radiation and chemotherapy. BNIP3 is expressed in
hypoxic regions of GBMs, but paradoxically, high BNIP3 expression does
not lead to cell death. BNIP3 is primarily located in the nucleus of most
GBMs, and that nuclear BNIP3 does not induce cell death in glioma cells.
These observations led to the hypotheses that BNIP3-induced cell death is
negatively regulated in brain tumors by nuclear localization of BNIP3. We
have found that BNIP3 plays a novel role in the nucleus of glial cells by
binding to a consensus sequence (CAGCCA) in the promoter regions of
genes involved in induction of cell death and silencing of these genes.
Previously, we determined that BNIP3 binds to the promoter of the
apoptosis-inducing factor (AIF) gene. BNIP3 recruits a repressor complex
to the AIF promoter, facilitating repression of transcription. Microarray
analysis of glioma cells differentially expressing nuclear BNIP3 indicated
that nuclear BNIP3 may down-regulate members of the TRAIL apoptotic
pathway, such as DR5 (death receptor 5). We confirmed that nuclear
BNIP3 down-regulates DR5 expression in glioma cells, subsequently block-
ing TRAIL-induced cell death. In addition, expression of nuclear BNIP3 in
primary GBM tumors correlates with decreased DR5 expression.
Pull-down assays confirmed that the BNIP3 protein binds to a consensus
binding site in the DR5 promoter. This study provides evidence for a novel
mechanism by which nuclear BNIP3 is selected for in GBM because its cell
death function is impeded and its transcriptional repression function of
genes such as DR5 is enhanced, thereby conferring a survival advantage to
the tumor cells.
CB-60. MICRORNA-125B (MIRNA-125B; CHR 11Q24; CHR
21Q21) FUNCTIONS IN THE PROLIFERATION OF HUMAN
ASTROGLIAL CELLS
W.J. Lukiw 1, J.G. Cui 1, Y.Y. Li 1, Y. Zhao 2, and F. Culicchia 3; 1Louisiana
State University Neuroscience Center, New Orleans; 2Department of
Structural Biology, University of Pittsburg; 3Louisiana State University
Department of Neurosurgery, New Orleans
MicroRNAs (miRNAs) are post-transcriptional modulators of gene
expression that regulate the stability and translation of their target messenger
RNAs (mRNAs). Here we report that the levels of a human brain-enriched
miRNA-125b are up-regulated in cultured human glioma cells and in
interleukin-6 (IL-6)-stressed normal human astroglial (NHA) cells, the
latter a treatment known to cause the proliferation of astroglial cells. An
anti-miRNA-125b (AM-125b) added exogenously to IL-6-stressed NHA
cultures attenuated astroglial cell proliferation and increased the expression
of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a known negative
regulator of cell growth. With a modified gel shift assay, the 3′-untranslated
region (3′-UTR) of CDKN2A was shown to strongly interact with
miRNA-125b (calculated free energy of association -26.2 kcal/mole). A
strong positive correlation between the astroglial cell markers glial fibrillary
acidic protein (GFAP) and vimentin, miRNA-125b abundance, and
CDKN2A down-regulation was noted in biopsied human glioma and glio-
blastoma and in several additional neurological disorders associated with
astroglial cell proliferation. These results suggest that miRNA-125b contrib-
utes to the cyclin-dependent proliferation of astroglial cells and that
anti-micro RNA strategies may be clinically useful in the treatment of
astroglial proliferative disease. (Support: Translational Research Initiative
[LSUHSC-NO] and an Alzheimer Association IIRG Award [WJL].)
CB-61. NF1 DEFICIENCY CONTRIBUTES TO GROWTH OF
GLIOBLASTOMA CELLS AND CONFERS SENSITIVITY TO MEK
INHIBITION BY PD0325901
Wendy See and Russell Pieper ; UCSF
INTRODUCTION: NF1 patients harbor mutations in a gene (NF1) that
encodes neurofibromin, a GTPase-activating protein (GAP) that negatively
regulates Ras activity. While NF1 patients have a 5-fold increased risk of
developing glioblastoma, mutations, deletions, and reduced expression of
NF1 have also been identified in a subset of spontaneous glioblastomas,
suggesting that NF1 may contribute to glioblastoma formation.
Furthermore, because NF1-deficient AMLs are sensitive to inhibitors of
MEK, a downstream effector of Ras, NF1 loss may be a driver of gliomagen-
esis and serve as a target for therapy. We investigated the contribution of
NF1 loss to development of human glioblastoma and whether NF1
mutations define a subset of tumors that may be more susceptible to targeted
therapies. METHODS: We obtained two glioblastoma cell lines, U251 and
LN229, that exhibit homozygous loss of NF1. Cells were transfected with
NF1-GFP or GFP alone, labeled with BrdU, fixed, and stained with
anti-BrdU primary and fluorescently labeled secondary antibodies. BrdU
incorporation was detected in GFP-expressing cells by flow cytometry as a
measure of proliferation. Next, U251 and LN229 cells were treated with
increasing doses of PD0325901, an MEK inhibitor, cultured for 5 days,
and subsequently counted. RESULTS: Transfection with full-length
NF1-GFP caused a significant decrease in BrdU uptake compared with
GFP in U251 and LN229 cells. Treatment with PD0325901 caused a
marked decrease in cell growth in LN229 cells (IC50 ¼ 30nM–100nM).
By contrast, U251 cells were more resistant to growth inhibition by
PD0325901 (IC50 ¼ 300nM–1000nM). CONCLUSIONS: Re-expression
of full-length NF1 in NF1-deficient glioblastoma cells leads to decreases in
proliferation, supporting NF1 as a tumor suppressor in human glioblastoma.
Treatment with PD0325901, a potent MEK inhibitor, inhibits glioblastoma
cell growth and suggests that at least a subset of glioblastoma patients may
respond to clinically relevant MEK inhibitors.
CB-62. DRUG SENSITIVITIES IN MOLECULAR SUBGROUPS OF
GBM-DERIVED BRAIN TUMOR STEM CELLS
Artee Luchman , Owen Stechishin , Stephanie Nguyen , John Kelly ,
Michael Blough , Gregory Cairncross , and Samuel Weiss ; University of
Calgary
Brain tumor stem cells (BTSCs) have been identified as primordial tumor
cells that may initiate disease and tumor recurrence as well as confer resist-
ance to existing treatment modalities. We have successfully isolated and
propagated a large array of BTSC lines from glioblastoma multiforme
(GBM) that display the fundamental cancer stem cell properties of clono-
genic self-renewal, multi-lineage differentiation and aggressive tumor-
initiating capacity. The frequent alteration of EGFR and PTEN in GBM
suggests that these two genes are integral to the molecular pathology of a
subset of GBMs and their BTSCs. We have identified subgroups with differ-
ent combinations of EGFR and PTEN mutations within our BTSC lines.
Here we investigate whether these subgroups display differences in
growth characteristics, in vitro signaling, and drug sensitivities. Our pre-
liminary results indicate that these mutational combinations impact
diverse intracellular signaling pathways downstream of EGFR and PTEN.
Furthermore, the specific subgroups have varying responses to the inhibition
of single classical pathway components. We demonstrate that combinatorial
inhibition of various pathway targets (EGFR, PI3K, Ras/MAPK, and PKC),
predicted by the mutational status and signaling signatures of each sub-
group, results in highly effective inhibition of BTSC growth in vitro.
Therapies that target alterations specific to tumor cells, especially tumor-
initiating BTSCs, hold the promise of providing efficacious treatment with
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decreased toxicity to normal tissues. We plan to further investigate the
application of targeted drug combinations in orthotopic xenograft mouse
models.
CB-63. ABERRATIONS IN HIPPO SIGNALING IN GBMS—A
POSSIBLE CONNECTION TO MESENCHYMAL PHENOTYPE
Sagar R. Shah , Ahmed Mohyeldin , Hadie Adams , Tomas Garzon-Muvdi ,
Colette Aprhys , and Alfredo Quinones-Hinojosa ; Johns Hopkins School of
Medicine
INTRODUCTION: Developmentally, Hippo pathway controls organ size
by regulating cell proliferation and apoptosis. Upon activation of this
pathway, a signaling cascade ensues that results in the inactivation of YAP,
a transcriptional co-activator of this pathway. Over-expression of YAP has
been implicated in several cancers. Research indicates that changes in
Hippo signaling induces epithelial to mesenchymal transformation, promot-
ing a more aggressive tumor. Recent studies identified a molecular subclass of
glioblastomas (GBMs) with a mesenchymal phenotype that is synergistically
driven by STAT3 and C/EBP-beta. Thus, we hypothesize that possible aber-
rations in Hippo signaling may give rise to this aggressive subclass of GBMs.
METHODS: Western blot, immunocytochemistry, qRT-PCR, Kaplan-Meier
analysis. RESULTS: Supporting possible aberrant Hippo signaling, 78% of
GBMs exhibit over-expression of YAP, which correlates with poor patient
survival (p ≤ 0.05). Furthermore, we demonstrate YAP nuclear localization
and activation of downstream targets, including Mcl-1 and CTGF. In
addition, 87% of GBMs that exhibit a mesenchymal phenotype show
increased expression of YAP. Thus, a high correlation (p ≤ 0.05) is observed
between YAP over-expression and co-expression of STAT3 and C/EBP-beta.
Contrary to previous reports, expression of merlin, a negative regulator of
YAP, is lost in only 21% of GBMs. Thus, other upstream regulators, such
as FAT3, must be investigated to account for increased YAP expression in
GBMs. Based on Kaplan-Meier analysis, GBMs with 2-fold down-regulation
of FAT3 are associated with poor clinical outcome (p ≤ 0.05). Interestingly,
YAP is over-expressed in some gliosarcomas and metastatic tumors to the
brain. CONCLUSION: We show pronounced expression of YAP in
GBMs, gliosarcomas, and metastatic tumors to the CNS. Furthermore, we
demonstrate that in addition to merlin, down-regulation of FAT3 may
account for this ectopic YAP expression. Moreover, this aberrant expression
promotes a mesenchymal phenotype. Understanding the role of Hippo
pathway in these tumors will have important implications in the manage-
ment of these malignant diseases.
CB-64. ABERRANT LOCALIZATION OF THE GUANINE
NUCLEOTIDE EXCHANGE FACTOR, ECT2: IMPLICATIONS
FOR INVASION AND MIGRATION
Adrienne C. Weeks , Andres Restrepo , Vedant Arun , Stacey Ivanchuk ,
Christian Smith , and James T. Rutka ; Hospital for Sick Children
Despite concerted efforts in the field of neuro-oncology, malignant
gliomas remain a treatment challenge even with the best medical and surgical
management. We have found the cytokinetic protein ECT2 to be elevated in
gliomas in a progression- and prognosis-dependent manner. In contrast to
normal human astrocytes, which maintain nuclear ECT2 expression,
primary human GBM and GBM cell lines exhibit expression of ECT2 in
the cytoplasm and the leading edge of migrating cells. This ectopic
expression results in activation of the pro-migratory small cytoskeletal
GTPases RAC1 and CDC42. Using a mouse xenograft model, we implanted
glioma cells expressing an inducible shRNA to ECT2. Mice with diminished
ECT2 expression, as compared with controls, had a dramatic increase in sur-
vival and a decreased incidence of tumor formation. Only 6/15 of ECT2
experimental mice formed tumors, despite evidence of implantation of
human cells, whereas all controls (25/25) formed tumors. Interestingly,
staining of normal glial and neuronal progenitors also revealed a cytoplasmic
expression pattern of ECT2, suggesting that in gliomas, ECT2 re-acquires a
progenitor phenotype. Using mass spectrometry to discover candidate pro-
teins that may be responsible for ECT2 cytoplasmic localization, we have
identified the RNA processing/cytoplasmic RNA granule protein
HnRNPA2/B1 and the polarity protein ZO-1 as novel ECT2 interactors.
The potential functional relevance of these interactions in the context of
cytoplasmic ECT2 are currently being explored to reveal a novel regulatory
paradigm of migration and invasion in gliomas.
CB-65. SONIC HEDGEHOG ACTIVITY IS REQUIRED FOR
CXCR4 SIGNALING IN CEREBELLAR GRANULE PRECURSOR
NEURONS AND MEDULLOBLASTOMA
Rajarshi Sengupta 1, Lihua Yang 1, Silvia Burbassi 2, Bo Zhang 1, Shirley
L. Markant 3, Zeng-jie Yang 3, Olimpia Meucci 2, Robert J. Wechsler-Reya 3,
and Joshua B. Rubin 1; 1Washington University in St. Louis; 2Drexel
University; 3Duke University
Intracellular signaling mediated by the chemokine CXCL12 and its
G-protein coupled receptor CXCR4 plays a crucial role in central nervous
system development as well as the genesis of the most common malignant
brain tumor of childhood, medulloblastoma. In each case, CXCL12 works
together with sonic hedgehog (Shh) to regulate proliferation. Evidence in
the literature suggests that CXCL12 modulates Shh-induced cerebellar
granule neuron precursor cell (GNP) proliferation through the inhibition
of intracellular cAMP levels. The aim of the current study was to determine
whether activation of the Shh pathway can reciprocally regulate CXCR4
expression and/or function. Notably, previous work from our lab has
demonstrated potential cross-talk between CXCR4 and other signaling
systems in the brain, such as opioids (m opioid receptor) and neurofibromin
(NF). The effect of Shh on CXCR4 function was examined in GNPs as well
as in Daoy medulloblastoma cells, which exhibit constitutive activation of
the Shh pathway. We found that in GNPs, Shh can strengthen coupling of
CXCR4 to activation of Gi and its downstream pathways, including
CXCL12-induced cAMP suppression, calcium flux, and ERK/Akt acti-
vation. Interestingly, in the Daoy cells, treatment with the Shh inhibitor
cyclopamine blocked CXCR4-induced Gai activation and downstream sig-
naling. In either case, changes in CXCR4 activity required long-term (12
hours) treatment with either Shh or cyclopamine and involved alterations
in the cell surface levels of the receptor. Overall, this study demonstrates a
potential positive feedback mechanism whereby Shh enhances surface
levels and hence overall signaling through CXCR4, which in turn amplifies
Shh function through suppression of cAMP. Such interactions could result
in novel signaling functions relevant to the regulation of proliferation, survi-
val, and cellular migration in those circumstances during normal develop-
ment and tumorigenesis when these pathways are co-activated.
CB-66. RESISTANCE TO EGFR INHIBITION VIA THE
EMERGENCE OF EGFRVIII-INDEPENDENT TUMOR
GROWTH-PROMOTING MECHANISMS IN GLIOBLASTOMA
Jill Wykosky 1, Akitake Mukasa 2, Lynda Chin 3, Webster Cavenee 1, and
Frank Furnari 1; 1Ludwig Institute for Cancer Research; 2University of
Tokyo; 3Dana-Farber Cancer Institute
The exact mechanisms of resistance to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) remain largely unknown in glioblas-
toma (GBM), despite the fact that amplification of EGFR and/or the
expression of constitutively active EGFRvIII are among the most frequent mol-
ecular alterations in this disease. Recently, we showed that U373 cells expres-
sing doxycycline (dox)-repressible EGFRvIII were dependent upon expression
of this receptor for tumor initiation and maintenance in a xenograft mouse
model. EGFRvIII silencing caused an extended period of growth stasis, after
which some tumors regained the ability to grow rapidly, in striking similarity
to the clinical scenario of resistance. These breakthrough tumors, termed
“escapers,” remained silenced for EGFRvIII and employed distinctly different
signaling pathways when collectively compared to EGFRvIII-dependent
tumors. Escapers exhibited elevated activity of the MAPK pathway, and
cells derived from the tumors were more sensitive to Mek inhibition than
cells from EGFRvIII-dependent tumors. Re-expression of EGFRvIII in esca-
pers markedly suppressed tumor growth, suggesting that the unique signaling
preferences of escapers are not compatible with those pathways preferentially
utilized by EGFRvIII. Genes were identified by microarray analysis that were
specifically expressed at higher levels in the escapers. These genes represent
candidates for involvement in the process of overcoming EGFRvIII
dependence and thus may contribute to resistance to EGFR inhibition.
Significantly, escaper cells were resistant to the in vitro growth-inhibitory
effects of the TKI gefitinib as measured by colony formation in soft agar.
Thus, the emergence of EGFRvIII-independent tumor growth-promoting
mechanisms in escapers is characterized by a switch in pathway signaling pre-
ferences and the up-regulation of novel genes and confers resistance to EGFR
inhibition. The genes and pathways identified may shed light on novel mech-
anisms of TKI resistance and point to potential targets for the development of
agents that could be used in combination with TKIs to circumvent resistance
while improving clinical response.
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CB-67. TRANSCRIPTIONAL DISTINCTIONS BETWEEN
A2B5-DEFINED HUMAN GLIAL PROGENITOR CELLS AND
THOSE DERIVED FROM GLIAL TUMORS AT ALL STAGES OF
GLIOMAGENESIS
Romane M.Auvergne 1, Fraser J.Sim 2, SuWang 2, DevinChandler-Militello 2,
JaclynBurch2, XiaojieLi2, AndrewBennet2, NimishMohile 2, WebsterPilcher 2,
Kevin Walter2, Mahlon Johnson 2, PragathiAchanta 3,
Alfredo Quinones-Hinojosa3, Sridaran Natesan4, and Steven A.Goldman 2;
1University of Rochester Medical Center; 2University of Rochester Medical
Center, Rochester; 3Johns Hopkins University, Baltimore; 4Sanofi-Aventis,
Cambridge
Resident progenitor cells of the adult white matter are a potential source of
primary glial tumors of the forebrain. The adult human brain contains a
population of glial progenitor cells that can be isolated on the basis of
ganglioside epitopes recognized by the A2B5 antibody (Nature Med 9:239,
2003; Ann Neurol 59:763, 2006). In this study, we used A2B5-based selec-
tion to isolate a population of tumor-initiating progenitor cells from human
gliomas and then used a substractive genomic strategy to identify the
transcriptional events associated with their oncogenesis. A2B5+ cells
were abundant in human gliomas at all stages of tumor progression.
Glioblastoma-derived A2B5+ cells demonstrated self-renewal and multiline-
age differentiation potential in vitro and were tumorigenic after transplan-
tation into the brain of immunodeficient mice in vivo. We further
compared the gene expression profiles of A2B5+ cells isolated from low-
grade (n ¼ 10) and high-grade gliomas (n ¼ 10) to those of their non-
neoplastic adult A2B5+ counterparts (n ¼ 8). While most of the genes
that were differentially expressed by at least 3-fold (1% FDR) by glioma-
derived A2B5+ tumor cells varied as a function of tumor stage, our analysis
identified a discrete cohort that was differentially expressed at all stages of
gliomagenesis as well as a select group that was differentially regulated in
low-grade gliomas. Real-time qPCR and immunolabeling confirmed the
differential expression of these genes. Pathway analysis revealed a major dys-
regulation of the TGF-beta and Wnt/beta-catenin pathways, suggesting a
key role of these pathways in the transformation of glial progenitors as
well as in the pathogenesis of both low- and high-grade gliomas. By compar-
ing the gene expression profiles of glial tumor progenitor-like cells isolated
from low- and high-grade gliomas to their non-neoplastic homologues, we
have identified a discrete set of genes and pathways by which glial tumorigen-
esis may be both better understood and more efficiently targeted.
CB-68. ELUCIDATION OF THE RELEASE AND FUNCTION OF
MONOMERIC EPHRINA1 IN GLIOBLASTOMA MULTIFORME
Amanda S. Beauchamp 1, Denise M. Gibo 1, Jill Wykosky 2, and
Waldemar Debinski 1; 1Wake Forest Health Sciences; 2Ludwig Cancer
Institute
INTRODUCTION: A monomeric functional form of ephrinA1 is released
by proteolytic cleavage from glioblastoma multiforme (GBM) cells.
Activation of the EphA2 receptor by ephrinA1 leads to a decrease in the
oncogenic properties of GBM cells. However, the exact mechanism of
release of ephrinA1 from the cell membrane is unknown, as are the exact
downstream effects of EphA2 receptor activation in GBM by both the
soluble and membrane-bound forms of ephrinA1. METHODS: We used
broad-spectrum inhibitors of serine proteases and matrix metalloproteinases
(MMP) as well as specific inhibitors of MMPs in addition to generating
ephrinA1 mutants interfering with the potential mechanism of its release.
Specific recombinant MMPs were also used to treat ephrinA1-transfected
U-251 MG GBM cells and to treat a recombinant ephrinA1 protein to deter-
mine which MMPs could lead to the cleavage of ephrinA1. Additionally, a
phosphorylation antibody array was used to identify candidates mediating
the effects of ephrinA1 on EphA2-expressing GBM cells. RESULTS:
GM-6001, an MMP inhibitor, and AEBSF, a serine protease inhibitor, pro-
minently decreased the release of ephrinA1 from GBM cells. An ephrinA1
mutant that is truncated upstream of the membrane anchorage site did not
demonstrate any decrease in the release from GBM cells. Additionally,
ephrinA1 treatment (10 minutes) caused the phosphorylation of genes such
as Fgr, a negative regulator of cell migration and adhesion, and FRK, a posi-
tive regulator of PTEN. EphrinA1 also led to an increase in the phosphoryl-
ation of FGRFs. CONCLUSIONS: The proteolytic cleavage releasing
ephrinA1 takes place in response to not only an MMP but also to serine pro-
tease(s), and the exact nature of the proteases involved is under further inves-
tigation. Moreover, monomeric ephrinA1 is able to induce significant
changes downstream of EphA2 activation within the GBM cell that could
be involved in the overall tumor-suppressing properties of ephrinA1.
CB-69. RB/E2F: GATEKEEPERS OF AUTOPHAGY AND
APOPTOSIS IN GLIOMA CELLS
Hong Jiang , Vanesa Martin , Candelaria Gomez-Manzano , David
G. Johnson , Marta Alonso , Erin J. White , Jing Xu , Timothy McDonnell ,
Naoki Shinojima , and Juan Fueyo ; The University of Texas MD Anderson
Cancer Center
Autophagy is a cellular stress response that protects cells from harmful
conditions. Emerging evidence suggests that this cellular process is also a
tumor suppressor pathway. Previous studies showed that cyclin-dependent
kinase inhibitors (CDKIs) induce autophagy. Whether retinoblastoma
protein (RB), a key tumor suppressor and downstream target of CDKIs,
induces autophagy is not clear. Here we first demonstrate that RB triggers
autophagy in human sarcoma osteogenic (Saos-2) cells, hepatoma (Hep3B)
cells, and brain tumor stem cells (MDNSC23), as indicated by accumulation
of LC3B, a punctate pattern of GFP-LC3 cellular localization, and the
double-membrane trimmed vacuole formation in the cytoplasm shown by
transmission electron microscopy. Autophagy flux study with double-labeled
EGFP-mRFP-LC3 fusion protein reveals that RB induces complete matu-
ration of autophagosome into autolysosome. In addition, RB activators
p16INK4a and p27/kip1 induce autophagy in RB-expressing sarcoma osteo-
genic (U2OS) cells and malignant glioma (U-87 MG) cells in an
RB-dependent manner. Furthermore, RB with deletions in the E2F1
binding region fails to induce autophagy, and overexpression of E2F1
antagonizes RB-induced autophagy, leading to apoptosis. Consistently,
down-regulation of E2F1 in U-87 MG cells results in high levels of autop-
hagy. Overall, our data reveal that RB induces autophagy by repressing
E2F1 activity. We speculate that this newly discovered aspect of RB function
provides one of the mechanisms by which RB acts as a tumor suppressor in
cancer development, and resistance to cancer therapy is correlated with RB
status.
CB-70. TNF-ALPHA-INDUCED CELL DEATH OF PRIMARY
HUMAN BRAIN MICROVESSEL ENDOTHELIAL CELLS: ROLE
OF P38 MAP KINASE AND REGULATION BY THE MATRIX/
INTEGRINS
M.R. Sandhya Rani 1, Ping Huang 2, Richard Prayson 3, Hirad Hedayat 4,
Andrew E. Sloan 4, Amy Novacki 5, Manmeet S. Ahluwalia 6, Russell Tipps 2,
and Candece L. Gladson 7; 1Cancer Biology, Cleveland Clinic; 2Cancer
Biology, Cleveland Clinic, Cleveland; 3Anatomic Pathology, Cleveland
Clinic, Cleveland; 4Brain Tumor and Neuro-Oncology Center, University
Hospital-Case Medical Center, Cleveland; 5Quantitative Health Sciences,
Cleveland Clinic, Cleveland; 6Brain Tumor and Neuro-Oncology Center,
Cleveland Clinic, Cleveland; 7Cancer Biology, Brain Tumor and
Neuro-Oncology Center, Cleveland Clinic, Cleveland
TNF-alpha induces the death of primary human brain microvessel endo-
thelial cells (MvEC) in a dose-dependent manner through TNF-R1 activation.
To determine whether TNF-R1 could be therapeutically manipulated on
tumor-associated endothelial cells in glioblastoma tumors, we evaluated the
expression of TNF-R1 on the endothelial cells in 31 human glioblastoma
tumor biopsy samples and 30 normal brain samples by immunohistochemis-
try. We found a significantly increased expression of TNF-R1 and
TNF-alpha on the endothelial cells in the tumor biopsies as compared to the
normal brain samples. We then investigated the regulation of TNF-R1
pro-apoptotic signaling in normal brain MvEC and found that the extracellu-
lar matrix (ECM) protein that the MvEC are adherent to or the integrin recep-
tor that is engaged regulates the pro-death signal on TNF-alpha stimulation.
TNF-alpha stimulation readily induced cell death of normal brain MvEC
plated on collagen, but a significantly reduced amount of cell death was
seen when normal brain MvEC were plated on vitronectin. We investigated
whether different downstream signals were activated when the normal brain
MvEC were plated on the different matrices and stimulated with TNF-alpha
and found a time-dependent phosphorylation of p38 MAP kinase in the
cells plated on collagen, suggesting that p38 MAP kinase is a downstream
effector for TNF-alpha-induced apoptosis. No phosphorylation of p38 MAP
kinase was observed in the MvEC plated on vitronectin. To substantiate the
clinical relevance of these findings, we examined the effect of TNF-alpha
stimulation on endothelial cells isolated from two different glioblastoma
tumors and found that TNF-alpha-induced cell death was similarly regulated
by the ECM or integrins. Our data suggest that TNF-R1 on tumor-associated
endothelial cells can be therapeutically manipulated as part of an antiangio-
genic therapy for glioblastoma tumors, and that the effectiveness of such a
therapy maybe in part dependent on the activity of specific integrins expressed
on the tumor endothelial cells.
Abstracts













CB-71. NUCLEAR PTEN-INDUCED AUTOPHAGY IS MEDIATED
THROUGH INDUCTION OF ER STRESS IN GLIOBLASTOMA
CELLS
Juinn-Lin Liu , Zhenyu Mao , Jing Xu , Juan Fueyo , and W.K. A. Yung ; The
University of Texas MD Anderson Cancer Center
The endoplasmic reticulum (ER) is an organelle critically involved in protein
folding and lipid and steroid biosynthesis as well as intracellular Ca2+ storage in
eukaryotic cells. Various physiological or pathological stimuli cause disruption
to these physiological functions of the ER, namely ER stress, and unfolded
protein response (UPR) is subsequently activated to restore the ER homeostasis.
However, prolonged and unresolved ER stress will ultimately lead to autophagy
and apoptosis. Induction of ERstress has thus emerged asa new anticancer strat-
egy based on the premises that UPR is often elevated in tumor cells compared
normal cells owing to a harsh microenvironment, such as hypoxia, glucose
deprivation, or misfolded mutant proteins. Tumor cells will be more sensitive
to small-molecule inhibitors that target components of UPR or inducers that
“super”-upload UPR. Several studies on ER stress in glioma cells have shown
promising results. In this report, we found that ER stress inducers triggered
autophagy much more prominently than PI3K/mTOR inhibitors and AMPK
activators did in U251MG cells. Interestingly, we also discovered that an
exogenous nuclear PTEN tumor suppressor could induce autophagy in
U251MG cells independent of its inhibition of mTOR and/or activation of
AMPK. Further analyses showed that UPR was enhanced, including
up-regulation of BiP/GRP78 and PERK-mediated inaction/phosphorylation
of eIEF2. Nuclear PTEN-induced autophagy could be attenuated only by inhibi-
tors of PERK but not GCN2 or PKR. In addition, nuclear PTEN could induce
autophagy and suppress self-renewal substantially in several glioma stem cell
lines. Whether this is mediated through induction of ER stress requires further
characterization. We propose that identification of the molecular targets specifi-
cally involved in nuclear PTEN-mediated, ER stress-induced autophagy will
provide a new therapeutic regimen for treating GBM more effectively.
CB-72. A REGULATORY ROLE FOR TAZ IN PRONEURAL TO
MESENCHYMAL DIFFERENTIATION IN GLIOBLASTOMA
Krishna Bhat 1, Katrina Salazar 1, Veerakumar Balasubramaniyan 2,
Brian Vaillant 1, Faith Hollingsworth 1, Joy Gumin 1, Kristen Diefes 1,
Dimple Patel 1, Frederick Lang 1, Howard Colman 1, and Kenneth Aldape 1;
1The University of Texas MD Anderson Cancer Center; 2University of
Groningen
Gene expression profiling studies have revealed that the mesenchymal signa-
ture (MES) is a predictor of poor survival and treatment resistance in glioblas-
toma (GBM) patients, whereas patients with a proneural (PN) signature
perform better in the clinic. Using bioinformatic approaches as well as exper-
imental testing of glioma stem cells (GSCs) and murine primary neural stem
cells (NSCs), we have found that the transcription co-factor WWTR1/TAZ
acts as a master regulator of PN to MES differentiation in GBM. TAZ is
epigenetically silenced in lower-grade/PN tumors, whereas its promoter is hypo-
methylated in GBM/MES tumors. Treatment with a demethylation agent
(2’-deoxy-5-azacytidine) induced dramatic increases in TAZ mRNA levels.
Silencing TAZ in GSCs decreased invasion and expression of multiple MES
genes and blocked tumorigenesis when implanted intracranially into mice.
Conversely, over-expression of TAZ in GSCs that lack this protein increased
MES gene expression and suppressed PN gene expression. Notably, these cells
showed increased invasion, differentiation toward an osteogenic lineage, and
tumorigenesis. In primary NSCs, over-expressing TAZ increased expression of
fibronectin and smooth muscle actin, both mesenchymal markers, whereas
astrocytic or neuronal differentiation was suppressed in response to serum.
All aforementioned phenotypes were abolished when over-expressing a single
point mutant version of TAZ (S51A) that lacks binding to its bona fide trans-
cription partner, TEAD. Intriguingly, when tested in chromatin immuno-
precipitation experiments, both PN and MES genes were direct targets of the
TAZ-TEAD4 complex. Currently, we are testing whether this complex delin-
eates specific epigenetic modifications at target gene loci, directly up-regulating
MES genes while down-regulating PN genes, by recruiting histone modifiers to
their promoters. Our studies have identified TAZ as an important master regu-
lator of PN to MES transition in gliomas and as an attractive therapeutic target.
CB-73. THE HELICASE PROTEIN DHX29 IS REQUIRED FOR
PROLIFERATION OF MALIGNANT GLIOMAS
Armen Parsyan 1, David Shahbazian 1, Tommy Alain 1, Yvan Martineau 1,
EmmanuelPetroulakis 1, OlaLarsson 1, ChristosGkogkas 1, IvanTopisirovic 1,
Geraldine Mathonnet 1, Gritta Tettweiler 1, Christopher Hellen 2,
TatyanaPestova 2, YuriSvitkin 1, and NahumSonenberg 1; 1McGill University;
2SUNY Downstate Medical Center
Translation initiation is a highly regulated step in protein synthesis.
Inhibition of translation initiation impedes cell growth and proliferation.
Several translation factors are implicated in tumorigenesis. We recently
showed that DHX29 is a novel translation initiation factor required for
tumorigenesis. DHX29 is a member of the DEAD/DExH-box protein
family. It functions as a helicase and stimulates translation initiation of
mRNAs with a structured 5′ untranslated region (5′UTR). The vast majority
of mammalian mRNAs contain some form of secondary structures at their
5′′UTR and as such might be a target of DHX29 regulation. We found
that DHX29 depletion impedes cancer cell growth in culture and in xeno-
grafts. We queried the ONCOMINETM database and found that DHX29
mRNA is significantly over-expressed in brain cancers. We validated the
data by showing that DHX29 protein is differentially over-expressed in
various brain cancer cells as assessed by immunoblotting. Depletion of
DHX29 from U87, U118, U251, U343, and U373 glioma cells resulted in
a substantial decrease in cell proliferation rate and cell viability. DHX29
silencing caused a cell cycle arrest in U87 and U251 cells, with an increased
number of cells in the subG0 phase. DHX29 silencing caused a dramatic
decrease in the number of colonies formed by the U87 glioma cell line as
assessed by a focus formation assay. This indicates that depletion of
DHX29 leads to a reduction of the malignant and proliferative properties
of the brain cancer cells and that silencing of DHX29 is sufficient to
impair tumorigenicity. Therefore, translational inhibition through DHX29
depletion or pharmacologic targeting might represent a novel means by
which tumorigenesis can be repressed.
CB-74. NOVEL FUNCTION OF P14ARF IN HUMAN
GLIOMAGENESIS: REGULATION OF TFPI AND GLIOMA
MEDIATED COAGULATION
Abdessamad Zerrouqi , Beata Pyrzynska , and Erwin Van Meir ; Emory
University
The malignant progression of many tumors, including malignant gliomas,
involves the loss of the p14ARF tumor suppressor gene. This genetic altera-
tion occurs with the transition to high-grade glioma and precedes the associ-
ated pathological features of intravascular thrombosis, the formation of
hypoxic regions and dramatically increased neovascularization. The mech-
anisms underlying and possibly connecting these biological features are
poorly understood. The tissue factor pathway inhibitor-2 (TFPI2) is an extra-
cellular serine protease inhibitor that prevents initial blood coagulation reac-
tions. Given the high frequency of ARF gene deletions and the decreased
expression of TFPI2 with astrocytomas progression, ARF loss might be
one of the genetic events that dysregulates TFPI2 and promotes plasma clot-
ting and vascular thrombosis/hypoxia within gliomas. To examine novel
functions of ARF, we expressed the ARF gene in ARF-deficient glioma
cells and examined the expression level of TFPI2. Pharmacological inhibi-
tors, RNA interference, and CHIP assays were used to examine ARF
effects on TFPI2 transcription and plasma clotting triggered by gliomas.
Our findings show that ARF up-regulates TFPI2 at the transcriptional level
and significantly reduces the ability of glioma cells to promote plasma clot-
ting as demonstrated by the increase in coagulation time of plasma in
contact with ARF-induced versus ARF-uninduced glioma cells. ARF
increases c-jun phosphorylation as an immediate response to JNK activation
and subsequently the binding of the AP-1 transcription factor to its specific
sites located on the TFPI2 gene promoter. Furthermore, this new ARF’s sig-
naling axis is p53-independent. In summary, these data present the first evi-
dence of p14 ARF-mediated genetic control of plasma coagulation, initiated
by glioma cells through AP1-mediated activation of TFPI2 expression, and
suggest that therapies directed toward restoring ARF activity, TFPI2
expression, or TFPI2 activity could reverse the intratumoral thrombotic
cascade that may initiate hypoxia-driven malignant progression.
CB-75. MECHANISM OF CROSSTALK BETWEEN THE
NF-KAPPA-B AND STAT3 SIGNALING PATHWAYS IN GLIOMAS
George B. Twitty , Susan E. Nozell , Suk W. Hong , and Etty N. Benveniste ;
UAB
Glioblastomas (GBMs) are among the most common and deadly tumors of
the central nervous system. NF-kappa-B and STAT3 are transcription factors
that regulate the expression of genes that promote cell proliferation, apopto-
tic resistance, and angiogenesis. In gliomas, both NF-kappa-B and STAT3
are constitutively activated and may contribute to the processes of glioma-
genesis. While the precise mechanisms underlying constitutive NF-kappa-B
and STAT3 activation in GBMs are largely undefined, there are numerous
proteins and pathways dysregulated in GBMs that may cause NF-kappa-B
activation. Also, NF-kappa-B can induce the expression of IL-6, an activator
of STAT3. Therefore, we hypothesize that in gliomas, the aberrant activation
of NF-kappa-B may lead to and promote STAT3 signaling. To test this
hypothesis, we evaluated human glioma cells grown in the absence or
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presence of TNF-alpha, which activates NF-kappa-B. We found that
NF-kappa-B was activated and correlated with enhanced IL-6 mRNA and
protein expression, followed by STAT3 activation and the expression of
SOCS-3, a STAT3-dependent gene. Using cell lines that inducibly down-
regulate endogenous NF-kappa-B activity, we determined that the levels of
IL-6 and SOCS-3 were significantly reduced in the absence of
NF-kappa-B. These data suggest that NF-kappa-B, via the production of
IL-6, can activate the STAT3 signaling pathway. Moreover, in gliomas, the
dysregulation of NF-kappa-B signaling may promote STAT3 activation
and signaling. Therefore, this potential crosstalk between the NF-kappa-B
and STAT3 pathways may promote cellular processes that lead to the devel-
opment and/or progression of gliomas and thus may represent important
targets for therapeutic interventions.
CB-76. RASGRP3 INTERACTS WITH THE ACTIN-RELATED
PROTEIN ARP3 AND REGULATES THE MIGRATION OF
GLIOMA CELLS
Hae Kyung Lee , Susan Finniss , Cunli Xiang , Simona Cazacu , and
Chaya Brodie ; Henry Ford Hospital
Gliomas, the most frequent primary brain tumor, are characterized by
increased invasion into the surrounding normal brain tissue. Signaling path-
ways coupled to DAG production are highly active in glioma cells, mainly
downstream of the growth factor receptors EGFR and PDGFR. Similarly,
Ras proteins are activated in gliomas and play a role in their malignant phe-
notype. Although gliomas express high Ras activity, Ras-activating
mutations have not been identified in these tumors. RasGRP represents a
new family of GEFs that belong to the DAG/phorbol ester receptor family
and that act as Ras activators by promoting the acquisition of GTP to main-
tain the active GTP-bound form. We found that RasGRP3 regulates glioma
cell migration and invasion and that it activates the Ras and Rap1 proteins in
these cells. In addition, RasGRP3 activates the Erk and AKT pathways, and
AKT is partially involved in the effect of RasGRP3 on glioma cell migration.
To further delineate the molecular mechanisms underlying RasGRP3 effects,
we performed a pull-down assay followed by mass spectroscopy and ident-
ified the actin-related protein, Arp3, as a novel interacting protein of
RasGRP3. Using immunofluorescence staining and co-immunoprecipitation,
we validated the interaction of RasGRP3 and Arp3. We further found that
PMA, which induces the translocation of RasGRP3 to the peri-nuclear
region, increased the association of RasGRP3 and Arp3. Moreover, silencing
of Arp3 modulated the subcellular localization of RasGRP3 in control
and PMA-treated cells and partially decreased the effect of RasGRP3 on
the spreading and migration of glioma cells. These results implicate
RasGRP3 as an important regulator of glioma cell migration and indicate
that RasGRP3 acts in a Ras/AKT-dependent and Ras-independent,
Arp3-dependent manner to regulate this process. RasGRP3 protein is an
important link between the DAG, Ras signaling pathways and actin
polymerization and may represent an important therapeutic target in the
treatment of gliomas.
CB-77. RAL SIGNALING IN MEDULLOBLASTOMA:
BIOLOGICAL AND THERAPEUTIC OUTCOMES
Kevin F. Ginn 1, Amanda Wise 2, and Faris Farassati 2; 1Children’s Mercy
Hospital and Clinics; 2University of Kansas Medical Center
Medulloblastoma is one of the most common malignant central nervous
system tumors in children. Treatment is often associated with untoward
long-term effects, and new targeted therapies are needed for this devastat-
ing tumor. Ras, one of the most important proto-oncogenes involved in
human cancers, has been shown to be involved in the development of
neurological malignancies. We studied Ral (Ras-like) activation as a
novel downstream effector of Ras, with a goal of targeting this pathway
as a potential therapeutic strategy. Affinity precipitation analysis of active
RalA (RalA-GTP) in eight medulloblastoma cell lines revealed the majority
have some level of RalA-GTP. Six cell lines (DAOY, RES256, RES262,
UW228-1, UW426, and UW473) had significantly higher RalA-GTP than
the other two (D283 and D425). To further evaluate the Ral pathway,
we investigated the levels of RalBP1 and PP2A.In this scenario, RalBP1
was of special interest owing to its reported effects of conferring che-
motherapy resistance in other malignancies. RalBP1 was expressed in all
eight medulloblastoma cell lines. PP2A is a negative regulator of Ral, but
no inverse correlation was observed in our analysis. Further analysis of
the Ral pathway revealed strong expression of phospho-aurora kinase, an
activator of Ral. We then selected DAOY as a model cell line for further
evaluation of the outcome of inhibiting Ral expression. Using a lentivirus
expressing anti-RalA shRNA, we successfully inhibited Ral expression as
compared to a negative control virus. Upon treatment, we observed a
greater than 65% reduction in proliferation by day three post-infection.
We concluded that high levels of active RalA are needed for cell survival
in the DAOY cell line and may represent a new therapeutic target for
medulloblastoma. Our future work will focus on the evaluation of the
effects of inhibition of Ral signaling on the invasiveness and in vivo tumor-
igenicity of medulloblastoma cells.
CB-78. THE ING4 TUMOR SUPPRESSOR INDIRECTLY
SUPPRESSES STAT3 SIGNALING BY REDUCING IL-6
EXPRESSION
Susan E.Nozell , Suk W.Hong , George B.Twitty , Jr., Braden C.McFarland ,
and Etty N. Benveniste ; University of Alabama at Birmingham
ING4 is a tumor suppressor that is absent or mutated in gliomas.
Previously, we showed that ING4 attenuates the transcriptional activity of
NF-kappa-B. STAT3 is a transcription factor activated by IL-6. Both
NF-kappa-B and STAT3 regulate the expression of genes that promote cell
proliferation, apoptotic resistance, and angiogenesis. In gliomas, both
NF-kappa-B and STAT3 are constitutively activated and may contribute to
gliomagenesis. Because ING4 can attenuate the expression of NF-kappa-B
regulated genes, we hypothesized ING4 would indirectly inhibit the acti-
vation and/or transcriptional activity of STAT3 by reducing the levels of
IL-6, an NF-kappa-B regulated gene. To test this hypothesis, we evaluated
human glioma cells grown in the absence or presence of TNF-alpha, which
activates NF-kappa-B. We found that NF-kappa-B was activated within 15
minutes and IL-6 mRNA and protein were expressed within 30 minutes
and 1 hour, respectively, of TNF-\alpha stimulation. STAT3 was activated
and coincided with the expression of SOCS-3, a STAT3-dependent gene, at
2 hours post-TNF-alpha. Moreover, we determined that the levels of IL-6
and SOCS-3 were significantly reduced in the absence of NF-kappa-B p65.
These data suggest that NF-kappa-B, via the production of IL-6, can activate
the STAT3 signaling pathway. Next, we assessed the impact of ING4 on
STAT3 signaling using U251-TR/F-ING4 cells, which inducibly express
exogenous ING4 expression in an ING4-null background. In these cells,
TNF-alpha induced NF-kappa-B activation, and IL-6 and SOCS-3 mRNA
expression in the absence of ING4. However, the levels of IL-6 and
SOCS-3 were significantly reduced when ING4 was co-expressed in these
cells. Together, these data indicate that ING4 attenuates NF-kappa-B
activity and reduces the levels of IL-6, and thus ING4 indirectly inhibits
the activity of STAT3. Therefore, the loss of ING4 expression/activity in
gliomas may explain why both the NF-kappa-B and STAT3 signaling path-
ways are constitutively activated.
CB-80. DIVERSITY OF ENGRAFTMENT BEHAVIORS AMONG
CD133-EXPRESSING PATIENT-DERIVED BRAIN TUMOR CELL
LINES
Christine Brown and Michael Barish ; Beckman Res Inst City of Hope
INTRODUCTION: Brain tumors can be thought of as heterogeneous
tissues developing within a complex brain environment. We are working
to achieve understanding of tumor initiation, progression, and dissemination
using populations of well-characterized patient-derived brain tumor cell
lines. METHODS: We derived pools of patient-derived glioma cells,
lentivirus-transduced them to express fluorescent tracking proteins, and
implanted them in immunodeficient mice. Patterns of engraftment were
assessed at different time points post-implantation by wide-field and confo-
cal microscopy of serial cryostat sections. RESULTS: Drawing on a library of
characterized patient-derived glioma lines, we focused on two lines, PBT003
and PBT008, both of which form tumor spheres expressing the putative
tumor stem cell marker CD133 in culture and show multipotential differen-
tiation under appropriate growth conditions. Histological analyses revealed
very different patterns of engraftment. By 2 months post-implantation,
PBT003 cells formed a tumor mass surrounded by peripheral disseminating
cells. In contrast, PBT008 cells were found scattered through cortex but had
not initiated tumor foci. We are working to understand the underlying
biology of this diversity of in vivo behaviors. CONCLUSION: Despite simi-
larities of marker expression and in vitro growth and differentiation patterns,
presumed populations of tumor-initiating cells can display wide variation in
characteristics of in vivo engraftment. Understanding mechanisms under-
lying these differences will enhance our understanding of glioma dissemina-
tion and secondary focus initiation.
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CB-81. VARIABILITY OF RESPONSE TO TEMOZOLOMIDE
TREATMENT IN ORTHOTOPIC GBM NEUROSPHERE
XENOGRAFTS REFLECTS PARENTAL TUMOR MOLECULAR
DIVERSITY
Ana C. deCarvalho , Laura Hasselbach , Kevin Nelson , Nancy Lemke ,
Lonnie Schultz , and Tom Mikkelsen ; Henry Ford Hospital
BACKGROUND & OBJECTIVE: Temozolomide (TMZ), a cytotoxic
DNA-alkylating agent, is employed in the standard of care of glioblastomas.
The methylation status of the promoter of the DNA repair protein
O6-methylguanine DNA-methyltransferase (MGMT) is a biomarker for
response to TMZ. Because this line of treatment remains palliative and has
only a modest effect on survival, the search for molecular vulnerabilities that
can be targeted in a combinational approach is warranted. We investigated
response to TMZ using glioblastoma multiforme (GBM) preclinical models
from patient-derived neurosphere cultures in search of candidate pathways
associated with TMZ resistance. EXPERIMENTAL APPROACHES:
Neurosphere cultures enriched in cancer stem cells were obtained from resected
tumors with different MGMT promoter methylation and TP53 status. GBM
neurospheres expressing luciferase were implanted intracranially in nude
mice. Tumor growth was monitored by noninvasive in vivo imaging using
the Xenogen IVIS System (Caliper Life Sciences). One 5-day cycle of TMZ
was administered intragastrically to two groups of mice. One group received
treatment before tumor growth was detectable and the other after a significant
increase in bioluminescence was observed. Control mice were administered
vehicle alone. Response to treatment was monitored by bioluminescence,
overall survival, and molecular alterations. RESULTS: TMZ monotherapy sig-
nificantly increased the survival of xenografts from GBMs positive for MGMT
promoter methylation, while no effect on survival was observed for the xeno-
grafts obtained from GBMs with unmethylated status. There was no statistical
difference between the early and late treatment schedules. Molecular subtype
specific upregulation of genes associated with DNA repair and mesenchymal
lineage in TMZ-treated tumors in relation to untreated control xenografts
was observed. CONCLUSIONS: GBM models using neurospheres have reca-
pitulated the TMZ sensitivity expected on the basis of MGMT promoter
methylation of parental tumors, constituting an appropriate model to investi-
gate tumor subtype-specific pathway activation in response to therapy.
CB-82. EFFECTS OF DYSREGULATED HGF/CMET SIGNALING
ON CEREBELLAR DEVELOPMENT AND MEDULLOBLASTOMA
PATHOGENESIS
SaraOnvani , PaulKongkham, Christian A.Smith , and James T.Rutka ; The
Arthur and Sonia Labatt Brain Tumour Research Centre
Medulloblastoma (MB) is a primitive neuroectodermal tumor of the cerebel-
lum. HGF/cMET signaling plays a role in cerebellar development, and the
overactivation of this pathway has been implicated in several human malignan-
cies. Our genome-wide epigenetic screens on human MB cell lines and primary
tumor specimens have identified SPINT2/HAI-2, an HGF/cMET signaling
inhibitor, as a novel tumor suppressor gene that is frequently silenced by pro-
moter hypermethylation in MB. Furthermore, the aberrant activation of the
HGF receptor cMET tyrosine kinase has been associated with the pathogenesis
of MB. To determine whether mutation contributes to aberrant HGF/cMET
signaling in MB, we will perform a mutational analysis of SPINT1, SPINT2,
and cMET in a large cohort of primary human MB specimens. This can
provide direct genetic evidence implicating HGF/cMET signaling in MB
tumorigenesis. Furthermore, to assess the role of aberrant HGF/cMET signal-
ing on cerebellar development and MB pathogenesis, we will construct a trans-
genic mouse overexpressing a mutant, constitutively active form of cMET
specifically in the granule precursor cells of the developing cerebellum, which
are the suspected cells of origin for MB. Mice will be examined at various
ages to characterize the effects of upregulated cMET activity on cerebellar
development and will be observed for evidence of tumor formation. This
work will help provide greater insight into the involvement of HGF/cMET sig-
naling in the genesis of MB and will provide a valuable preclinical model for
testing the existing and novel HGF/cMET targeted antitumor agents.
CB-83. CURCUMIN AND TRAIL INDUCE APOPTOSIS IN
GLIOMA CELLS AND GLIOMA STEM CELLS VIA
DOWNREGULATION OF NOVEL PKC ISOFORMS AND
INHIBITION OF AUTOPHAGY
ArielBier 1, SusanFinniss 2, HagitHershkovitz 1, SaritKahana 1, CunliXiang 2,
SimonaCazacu 2, AnaDecarvalho 2, and ChayaBrodie 2; 1Bar-Ilan University;
2Henry Ford Hospital
TRAIL induces apoptosis in cancer but not in normal cells and is therefore
considered a promising antitumor agent. Some cancer cells, however, are
resistant to the apoptotic effect of TRAIL. We examined the effect of the
natural compound curcumin on the resistance of glioma and glioma stem
cells (GSCs) to TRAIL. Some of the glioma cell lines and primary glioma cul-
tures exhibited sensitivity to TRAIL, whereas all the GSCs were resistant to
both curcumin and TRAIL. Curcumin induced autophagy in glioma cells.
However, a combined treatment with curcumin and TRAIL abolished the
autophagy induced by curcumin and induced apoptosis in all the resistant
cells. PKC-epsilon and PKC-delta play a role in the sensitivity of glioma
cells to TRAIL. Curcumin or TRAIL alone did not induce significant
changes in the expression or cleavage of PKC-epsilon and PKC-delta in the
TRAIL-resistant cells. In contrast, combined treatment agents induced
some accumulation of the catalytic fragment of both PKC isoforms and sig-
nificantly decreased their expression. Overexpression of PKC-epsilon and
PKC-delta partially protected the cells from the apoptotic effect of curcumin
plus TRAIL. The caspase-resistant mutant PKC-epsilon D383A rendered the
cells more resistant to the combined treatment, whereas the caspase-resistant
mutant of PKC-delta exerted a smaller protective effect, suggesting an oppo-
site role of the cleavage of PKC-epsilon and PKC-delta in this effect.
Treatment of the cells with curcumin and TRAIL also decreased the
expression of AKT in a PKC-epsilon-dependent manner. In summary, curcu-
min sensitized glioma cells and GSCs to TRAIL by decreasing the expression
of PKC-delta and PKC-epsilon and by downregulating AKT downstream of
PKC-epsilon. The combined treatment of TRAIL and curcumin abolished the
induction of autophagy by curcumin and induced cell apoptosis. Combining
curcumin and TRAIL may be useful therapeutically in the treatment of
gliomas and the eradication of glioma stem cells.
CB-84. PDGF-DRIVEN GLIOMA MODEL REVEALS THAT
ENVIRONMENTALLY TARGETED THERAPIES MAY BE MORE
EFFECTIVE AT ALTERING RECURRENT DISEASE KINETICS
Susan C. Massey 1, Kristin R. Swanson 1, and Peter Canoll 2; 1University of
Washington; 2Columbia University
Glioblastoma multiforme is widely noted for its heterogeneous cellular
make-up, with greater heterogeneity correlated with higher levels of biologi-
cal aggressiveness. To better understand this correlation, we examined the
microenvironmental relationships between cell populations in a mathemat-
ical model for a platelet-derived growth factor (PDGF)-driven experimental
glioma model. Through the creation and parametrization of a mathematical
model of this experimental rodent model, we examined the effect of PDGF
signaling between three cell populations within the tumor: glial progenitor
cells that are infected with PDGF-expressing retrovirus, glial progenitors
that are not infected, and other normally present cells in the brain. By chan-
ging cell numbers or PDGF levels after the tumor has reached a magnetic res-
onance imaging (MRI)-detectable size in simulation, we examined the effects
of treatment on tumor recurrence patterns. Pre-operatively, our model shows
that tumors with high levels of recruitment are faster growing; post-
operatively, however, these tumors recur more quickly and continue a
growth pattern quantitatively similar to the pre-operative pattern. Blocking
recruitment as treatment leads to a delay in tumor growth and also to recur-
rence with a pattern of radial growth that is slower than pre-treatment
growth. Thus, the mathematical model for the PDGF tumor ecology suggests
traditional therapies such as resection that target nodular growth do not sig-
nificantly affect the tumor phenotype (in this mathematical experimental
model) that will appear on recurrence, whereas therapies that target the
tumor ecology (e.g., paracrine signaling via small molecular inhibitors like
bevacizumab) may affect the pattern of tumor growth upon recurrence.
This is consistent with recent reports that GBM patients treated with bevaci-
zumab have recurrent tumors that exhibit a more diffuse growth pattern.
EPIDEMIOLOGY
EP-01. RETROSPECTIVE STUDY OF THE GEOGRAPHIC
EFFECTS ON SURVIVABILITY OF POST-OPERATIVE
MALIGNANT PRIMARY CNS TUMORS REPORTED IN THE
SEER DATABASE
Blake Riebe 1, Chris S. Karas 2, Bradley Bagan 2, and Mirza N. Baig 2; 1Des
Moines University Medical School; 2Mercy Brain and Spine Center
OBJECTIVE: Our objective was to explore the geographic effects on the
postoperative survivability of primary malignant central nervous system
(CNS) tumors reported in the Surveillance, Epidemiology, and End Results
(SEER) database. METHODS: Using the SEER*Stat software available at
www.seer.cancer.gov/seerstat version 6.6.1 and the Incidence - SEER 17
Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov
2008 Sub (1973–2006 varying) database, survival rates of 22,380 patients
diagnosed with a malignant primary CNS tumor and who underwent
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